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Abstract
With the rapid expansion of HIV treatment programs across sub-Saharan Africa, substantial
progress has been made towards universal treatment accessibility in Uganda; however, new
healthcare challenges have been emerging, such as the development of drug-resistant HIV, which
threaten to undermine achievements made thus far. In order for HIV treatment to be effective,
people living with HIV (PLWH) must be highly adherent without missing a single dose, which
can be challenging for those also facing difficulties such as financial insecurity. In the context of
Kampala, Uganda’s urban capital, it has been suggested that healthcare accessibility is made
difficult by several physical and social barriers. However, knowledge of the extent to which such
barriers, especially geographical barriers might influence HIV treatment success is lacking. This
is a mixed methods study which examines geographical barriers to adherence within the socioeconomic context of Kampala. Using data from a survey administered to individuals on
treatment at the Joint Clinical Research Center (JCRC) in Kampala (n=149), the study employs
logistic regression to examine the association between geographical barriers and treatment
outcomes. Semi-structured interviews (n=30) were also conducted to deepen our understanding
of lived experiences with HIV treatment. Results were unexpected, suggesting that participants
living more than two hours away from the treatment facility were actually less likely to miss
their daily dose of medication (OR = 0.33, p < 0.05), compared to those living in proximity to
the treatment center. Findings from the interviews helped to explain these paradoxical findings,
as it was reported that PLWH prefer clinics further from their home to avoid being recognized.
The effect of HIV stigma was reported to further impact adherence at home and in workspaces,
as PLWH felt pressured to take medication in secrecy. The results of our regression suggested
that high-income employment (OR = 3.82, p < 0.05) and partnered relationship status (OR =
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4.28, p < 0.05) were predicted to increase the probability of missing doses. Challenges to HIV
treatment adherence such as stigmatization and transportation costs must therefore be considered
in conjunction with one another, as determinants of health are overlapping and inextricable.

Key Words: HIV treatment, Access to Healthcare, Accessibility, Transportation, Adherence,
Antiretroviral therapy, Uganda, sub-Saharan Africa
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Summary for Lay Audience
In recent decades, the development of HIV treatment medications has made it possible for those
diagnosed with HIV to live longer and healthier lives. Treatment programs are now widespread
across sub-Saharan Africa, including Uganda, with many programs offering medication for free.
However, research shows that people living with HIV can face challenges which prevent them
from accessing the medications, even though the medications are offered free of charge. For HIV
treatment to be effective, the medication must be taken consistently, without missing any doses.
Adherence can be defined as the degree to which someone takes their medication as prescribed.
This research thus examines potential barriers to adherence, such the distance to the treatment
center. In this study, 30 people on HIV treatment at the Joint Clinical Research Center (JCRC) in
Kampala, Uganda were interviewed about the challenges they face in adhering to treatment
regimens. Surveys were also completed by 149 people on HIV treatment at the JCRC.
Surprisingly, the survey data indicated that those who lived furthest from the clinic (over two
hours away) actually had the lowest probability of reporting missed doses. These unexpected
findings can be explained in the context of the results from the study’s one-on-one interviews. It
emerged from the interviews that those on HIV treatment prefer clinics further from their home
to avoid being recognized. Further, based on survey data, those with high-income employment
and a partner were most likely to report missing doses, compared to those who were unemployed
and single. The effect of HIV stigma was reported in the interviews to impact adherence at home
and in workspaces, as people on HIV treatment often feel pressured to take medication in
secrecy. These results are significant in that they provide direction for public health policies
which seek to maximize treatment success. The results suggest that stigma is an important
challenge faced by people on HIV treatment. Initiatives in and around Kampala should therefore
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seek to raise awareness surrounding HIV and HIV treatment, in order to minimize the
stigmatization of people living with HIV.
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Chapter 1: Introduction
This thesis examines experiences with the human immunodeficiency virus (HIV) and
HIV-treatment in Uganda. While there are two types of viruses (HIV-1 and HIV-2), the majority
of infections worldwide are caused by HIV-1 (World Health Organization, 2016). The focus of
this dissertation is HIV-1, and from this point on, HIV-1 will be referred to as “HIV”, for
simplicity. This chapter serves to introduce the research topic and define key processes related to
our research questions. An overview of the broader context of HIV/AIDS in Uganda is provided,
as well as a brief description of the main features of HIV treatment. The study’s research
questions and the structure of this dissertation are also included in this chapter.
1.1 Study Background
The HIV/AIDS Epidemic
Beginning in the 1980s, the HIV/AIDS epidemic has devastated populations across the
globe (Stoneburner, Sato, Burton, & Mertens, 1994). HIV is the retrovirus responsible for the
progressive disease known as AIDS (acquired immunodeficiency syndrome). If left untreated,
HIV compromises the immune system, leaving the body vulnerable to fatal opportunistic
infections. Due to an initial lack of familiarity with human retroviruses, HIV proved incredibly
difficult to manage clinically. Until the late 1990s, treatment options consisted largely of
measures to prevent opportunistic infections (Arts & Hazuda, 2012; Broder, 2011; Yoshimura,
2017).
HIV can be contracted through sexual intercourse, injection drug-use, as well as motherto-child transmission (Paquette, Demers, Gale-Rowe, & Wong, 2012). The risk of HIV
transmission varies substantially by sex act, presenting the greatest risk for men who have sex
1

with men (MSM). Although MSM and injection drug-users have a higher risk of infection,
heterosexual intercourse is the most common mode of transmission in regions where HIV is
endemic, such as sub-Saharan Africa (Kharsany & Karim, 2016; Paquette et al., 2012). In
heterosexual partnerships, biological vulnerability to HIV/AIDS is greater for the female sex as
well as those with other sexually transmitted infections (STIs). Vulnerability to HIV can be
further impacted by social factors such as gender and level of education (Chersich & Rees, 2008;
Jukes, Simmons, & Bundy, 2008; Turmen, 2003).
From the beginning of the epidemic, it is estimated that over 32 million people have died
from AIDS-related illnesses (UNAIDS, 2019). Despite the global scale of the HIV/AIDS
epidemic, sub-Saharan Africa remains the most severely affected geographical region, bearing
over 70% of the global burden of disease (Kharsany & Karim, 2016). Divergent patterns of
HIV/AIDS prevalence exist within sub-Saharan Africa; Many countries in West Africa have an
HIV prevalence of under 2%, while the prevalence of countries in East and Southern Africa have
been estimated at as high as 27% (Bongaarts, Buettner, Heilig, & Pelletier, 2008; World Bank,
2018b). Drivers of this variation in global disease distribution are heavily debated, with potential
factors including gender inequality, income disparity, and deficiencies in the quality of health
services (Bongaarts et al., 2008; Lurie & Rosenthal, 2010; Piot, Greener, & Russell, 2007).
The state of the HIV epidemic in Uganda is unique in that the nation was one of the first
to experience a drastic increase and subsequent reduction in HIV prevalence (Bessinger, Akwara,
& Halperin, 2003). In response to HIV prevalence rates as high as 18% during the 1980s, public
health initiatives were implemented in full force, including educational campaigns as well as the
promotion of condom use (Bessinger et al., 2003; Kagaayi & Serwadda, 2016; Ministry of
Health, 2019). With a prevalence of 5.7% in 2018, the country has made tremendous strides in
2

curbing disease transmission rates (World Bank, 2018b). Still, as of 2017, 1 in 7 households in
Uganda were reported to have at least one HIV-positive household resident, with an estimated
1.2 million HIV-positive adults in the country (Ministry of Health, 2019).
Combination Antiretroviral Therapy
Despite hurdles encountered in the early development of HIV treatment, over 40
antiretroviral (ARV) medications are currently available to manage the illness (Broder, 2011;
Yoshimura, 2017). However, ARVs cannot completely eliminate the HIV virus. Rather, a
combination of ARVs from various drug classes are prescribed to inhibit viral replication, thus
preventing the progression of the illness and the resultant immunosuppression (Arts & Hazuda,
2012; Zolopa, 2010). Laboratory tests help to gauge the progression of the virus by measuring
viral load, generally measured as the number of copies of viral RNA per millilitre of blood
(Hardon et al., 2006). With combination antiretroviral therapy (cART), HIV positive individuals
are able to attain a high quality of life and a life expectancy that is only marginally shorter than
those who are HIV negative (Yoshimura, 2017).
Uganda has also been a frontrunner in the scale-up of HIV treatment programs across the
African continent. Beginning in the early 2000s, cART has been included in the nation’s
HIV/AIDS control program (Atuyambe et al., 2008; Ndembi et al., 2011). Treatment coverage
rose steeply from around 200,000 individuals on treatment in 2009 to over one million as of
2018 (Ministry of Health, 2019; Ndembi et al., 2011). This progress has been met with
skepticism as it was believed that low-income countries such as Uganda might not be able to
meet the resource demands of long-term treatment programs (Byakika-Tusiime et al., 2005;
Ndembi et al., 2011). While cART programs have made it possible to live with HIV, the prospect
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of following a lifelong treatment regimen has created new challenges for Uganda’s HIV positive
population.
In order for treatment to be effective, individuals on cART must adhere to a strict
medication regimen without missing any doses (Hardon et al., 2006). Whether or not someone
takes their pills in a timely manner and at the prescribed dosage is termed ‘adherence’ (Ammon,
Mason, & Corkery, 2018). Imperfect treatment adherence gives the HIV virus the opportunity to
replicate and to compromise the immune system. Worse still, low levels of adherence can select
for drug-resistant variants of HIV, making the virus more difficult to treat (Hamers, Sigaloff,
Kityo, Mugyenyi, & De Wit, 2013).
Based on experiences in the United States and Europe, it is expected that with the
widespread implementation of cART programs, the prevalence of drug-resistant variants of HIV
should rise initially, and then stabilize over time (Hamers et al., 2011). Due to the early timing of
the cART roll-out, Uganda is currently experiencing a rapid increase in measured drug
resistance. Issues such as the inconsistency of drug supplies and the lack of virological
monitoring may exacerbate the emergence of drug resistance in resource-constrained nations
(Hamers et al., 2011; Ndembi et al., 2011). If resistance continues to develop rapidly, large
numbers of individuals on cART as well as newly diagnosed individuals will be forced to resort
to alternative lines of treatment, which cost around ten times more than first-line treatments
(Hardon et al., 2006). This will further marginalize patients struggling with adherence and result
in additional strains on regional health facilities.
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1.2 Research Problem
With the implementation of policies in 2011 which call for the free provision of cART at
public facilities in Uganda, treatment costs should no longer hinder medication adherence
(Church et al., 2015). However, other out-of-pocket expenses such transportation costs are often
reported as a substantial burden (Hardon et al., 2006). Consequently, a disproportionately high
level of drug resistance in Uganda, and in Kampala in particular, points to the need to investigate
other potential barriers to treatment (Hamers et al., 2011).
There is a lack of consensus in the literature concerning the impact of issues of
transportation and accessibility on treatment adherence in Uganda. As studies tend to focus on
rural areas, in-depth analyses of geographical barriers in urban areas of Uganda have not been
conducted. With the ever-changing urban landscape of Kampala and the evolution of treatment
programs, there is a need for up-to-date studies examining challenges to treatment adherence
such as accessibility.
In response, the overarching question for this thesis is “What are the barriers to cART
treatment adherence in Kampala, Uganda?”. To answer this overarching question, we aim to
answer the following specific research objectives:
-

To examine the influence of geographical barriers, such as time spent traveling to the
clinic, on treatment outcomes in the context of Kampala, Uganda.

-

To determine the impact of socio-economic variables such as income on HIV treatment
outcomes.

-

To explore the perceptions of individuals on cART with regards to HIV treatment
challenges in Kampala, Uganda.

5

1.3 Thesis Structure
This thesis is written in integrated article format, with the inclusion of two stand-alone
manuscripts. The dissertation is organized into six main chapters: Chapter 1 introduces the
research topic and provides key background information pertaining to HIV and HIV treatment.
Chapter 2 presents an overview of dominant discourse surrounding HIV treatment challenges in
Uganda, in addition to an outline of the evolution of UN global health objectives. The study’s
research methods are detailed in Chapter 3, including a summary of the theoretical perspectives
that inform the study. Chapter 4 includes the first manuscript, which investigates the relationship
between time spent travelling to the clinic and HIV treatment success in Kampala, Uganda.
Chapter 5 contains the second manuscript which explores the experiences and perception of
those on cART, regarding barriers to treatment success in Kampala. As both manuscripts are
stand-alone, they each contain sections which also detail methodology and existing literature. As
such, there is a degree of repetition in this dissertation. Lastly, Chapter 6 provides a brief
discussion of the study results, tying together the conclusions drawn in both manuscripts.
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Chapter 2: Review of the Literature on Challenges Associated with HIV Treatment
2.1 Introduction
This chapter presents a review of the literature surrounding the challenges associated with
HIV treatment, with a focus on experiences in Uganda. The chapter begins with an overview of
the UN global health objectives related to HIV, and progress achieved thus far. The importance
of adherence and the state of HIV treatment programs will then be established, followed by a
summary of barriers to treatment adherence as seen in the literature. The review will then focus
on how geography impacts HIV treatment adherence and accessibility. We will then situate
treatment adherence challenges in the social context of Uganda, examining how gender shapes
experiences with HIV.
2.2 United Nations Sustainable Development Goals and Global Health Objectives
For several decades, global health programs and partnerships headed by the United
Nations (UN) have been established to work towards the ultimate objective of eradicating
HIV/AIDS. Following the UN Millennium Summit in 2000, the eight Millennium Development
Goals (MDGs) were established to be achieved by 2015. Goal 6, to combat HIV/AIDS, malaria
and other diseases, included specific targets to achieve universal access to HIV treatment by
2010 (United Nations, 2008). The 3 by 5 initiative was established in 2003, with the goal of
getting 3 million people living HIV/AIDS on treatment by 2005, specifically in developing
countries. This objective was not met, with approximately 1.3 million people on treatment by the
end of 2005 (Hardon et al., 2006). The UN estimate of the proportion of people living with
HIV/AIDS in sub-Saharan Africa was approximately 37% in 2009 (United Nations, 2011).
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The Sustainable Development Goals (SDGs) replaced the MDGs in 2015, comprised of 17
development goals meant to be reached by 2030. Goal 3, to ensure healthy lives and promote
well-being for all at all ages, is the most closely related objective to HIV treatment. However, the
SDGs acknowledge the multifaceted nature of HIV/AIDS, and emphasize how goals such as
ending hunger are related to increasing positive treatment outcomes (United Nations, 2015;
World Food Programme, 2019). The newest targets for HIV treatment were developed under the
Joint United Nations Programme on HIV/AIDS (UNAIDS), aiming to have 90% of those
diagnosed with HIV on treatment by 2020 (UNAIDS, 2014). UNAIDS estimated the proportion
of people living with HIV on treatment to be 62% as of 2018 (World Bank, 2018a).
Unprecedented progress has been made to decrease morbidity and mortality associated
with HIV/AIDS (Bain, Nkoke, & Noubiap, 2017). Globally, over 23 million HIV positive
individuals were receiving treatment in 2018, with the majority living in Eastern and Southern
Africa (UNAIDS, 2019). However, in addition to the goal of 90% treatment coverage, the
ambitious 90-90-90 targets aim to diagnose 90% of all HIV-positive individuals, and to achieve
viral suppression for 90% of those on treatment by 2020. The enormous amount of resources
required to conduct continual virological monitoring and to ensure a consistent supply of ARVs
continue to threaten the feasibility of these targets. Further, difficulties in the collection of data
pertaining to HIV-treatment result in unreliable statistics, which make the evaluation of the
success of the UNAIDS targets incredibly challenging. Continued research and development of
HIV-treatment initiatives in low- to middle-income countries is crucial in order to maximize
resource allocation and the efficiency of cART programs (Bain et al., 2017).
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2.3 The importance of adherence to cART
Insufficient adherence to HIV treatment regimens is considered to be one of the main
causes of HIV/AIDS-related mortality and morbidity (Tuller et al., 2010; Weiser et al., 2010,
2003). It has been well established that imperfect adherence can cause an increase in viral load,
which can lead to immunosuppression (Bangsberg et al., 2000, 2001; Weiser et al., 2010). The
benchmark of 95% adherence has been recommended to optimize treatment outcomes and
maintain an undetectable viral load (at less than 50 copies/ml) (Paterson et al., 2000; World
Health Organization, 2016). Although it is possible for viral suppression to occur at levels of
adherence as low as 54%, it is recommended that those on cART to strive to take 100% of their
medication, in order to minimize the occurrence of opportunistic infections and prevent the
possibility of drug resistance (Bangsberg, 2006; Paterson et al., 2000).
In accordance with the latest WHO guidelines (2016), adults diagnosed with HIV should
be initiated on cART as soon as possible, giving priority to those in the advanced clinical stages
of HIV (i.e. with signs of a weakened immune system) (World Health Organization, 2016). It is
recommended for newly diagnosed individuals to begin on the first-line treatment consisting of
Tenofavir (TDF) + Lamivudine (3TC)/Emtricitabine (FTC) + Efavirenz (EFV). Alternative firstline medications may be substituted when these are unavailable although they may be less
effective and result in increased side-effects. Unfortunately, many people living with HIV in
Uganda are currently not using the most highly recommended combination of drugs (Ndashimye
et al., 2018). Further, when resistance to first-line treatment occurs as a result of low adherence,
individuals may be forced to begin second-line treatment. Second-line treatment can be ten times
more costly than first-line medications as it includes a different class of drug called a protease
inhibitor (Hardon et al., 2006). There is thus increased pressure to maintain high levels of
13

adherence in low-income countries, as the selection of medications is limited (Peltzer, Friend-Du
Preez, Ramlagan, & Anderson, 2010; Weiser et al., 2010).
Contrary to concerns that low-income countries would not be able to support cART
programs, levels of adherence observed in sub-Saharan African countries have often surpassed
those observed in high-income countries (Mills et al., 2006). A systematic review conducted by
Mills et al. (2006) reported that the proportion of those adherent (>95%) to their HIV treatment
regimen throughout Uganda ranged from 68%-98% (Mills et al., 2006). Interestingly, the
majority of the high-scoring studies were based in rural settings, and the study which reported
68% of individuals as adherent was based in Kampala (Byakika-Tusiime et al., 2005; Mills et al.,
2006). Still, other studies within Kampala reported mean levels of adherence ranging from 82%
to just under 95% (Oyugi et al., 2004, 2007). Although these levels of adherence meet and
surpass those reported in high-income countries, levels of adherence in cART programs are
expected to decline overtime, even when medication is provided free of charge (Nachega, Mills,
& Schechter, 2010). Regionally variable challenges such as lack of drug availability demand for
treatment initiatives to be tailored to the local context.
Recent studies have identified obstacles related to adherence which range from structural
barriers such as health service deficiencies to individual (patient-level) challenges. Frequently
cited barriers to adherence include food insecurity, stigma, side effects, waiting times, the
inconsistency of drug supplies, and transport time and cost (Ammon et al., 2018; ByakikaTusiime et al., 2005; Hardon et al., 2006; Weiser et al., 2010). While broad discussions of
adherence across sub-Saharan Africa point to common barriers, the existence and importance of
such barriers may vary substantially by factors such as age, cultural context, and geographical
region (Ammon et al., 2018). Issues related to transportation and accessibility have been
14

repeatedly identified as prohibitive obstacles in several eastern and southern African countries
including Botswana, Tanzania, Zimbabwe and Uganda (Chindedza, Mutseyekwa, & ChidemeMunodawafa, 2013; Hardon et al., 2006). Although, the extent to which transportation-related
issues compromise HIV treatment success is often unclear. In addition to contextual variation,
inconsistent methodology can result in a wide range of inferences about transportation
challenges. The following section will explore geographical barriers to HIV treatment as well as
the influence of social challenges on treatment outcomes.
2.4 The impact of geography on HIV treatment outcomes
Health geographers have been at the forefront of the studies of access and utilization of
health care services (Rosenberg & Hanlon, 1996). Many related studies have investigated
geographical challenges such the association between transportation and cART adherence,
though results range considerably depending on the manner in which transportation barriers were
assessed. Overall, transportation barriers have often been shown to negatively impact adherence
in sub-Saharan Africa; however, other studies exist which show a lack of association between
geographical challenges and treatment success. For instance, a study by Billioux et al. (2018)
calculated the distance traveled to cART facilities in rural Uganda, using online maps. By
comparing distances traveled by those who are virally suppressed and those who are virally
unsuppressed, Billioux et al. (2018) found no significant difference between the two groups.
Byakika-Tusiime et al. (2005) also found no association between distance traveled to clinic and
adherence to cART in Kampala. A few studies even indicated a reverse relationship, whereby
those who reported geographic barriers were more likely to report an increase in positive HIV
care and treatment outcomes (Lankowski, Siedner, Bangsberg, & Tsai, 2014). Linking
measurable indicators of treatment success to quantitative measures of geographical barriers has
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proven to be quite challenging. However, qualitative and descriptive studies continue to identify
such issues as primary barriers to HIV care and treatment in Uganda (Hardon et al., 2006;
Lankowski et al., 2014; Tuller et al., 2010). There is thus a need to further investigate the effects
of transportation challenges on treatment adherence by situating quantitative findings in the
context of the lived experiences of people living with HIV in Uganda.
In Uganda, the costs associated with transport to HIV treatment facilities are substantial
in comparison to the cost of living expenses (Tuller et al., 2010). Although income levels tend to
be higher in urban areas of Uganda, transportation charges are proportionately raised (Uganda
Bureau of Statistics, 2018b). Compounding issues of cost, transportation through Kampala can
be time consuming and even dangerous, considering the high incidence of road traffic accidents
in the region (Balikuddembe, Ardalan, Khorasani-Zavareh, Nejati & Munanura, 2017). Several
studies have identified transportation as one of the main reasons people in Uganda failed to get
tested or even initiated on cART (Lankowski et al., 2014). Those on cART in Uganda reportedly
struggle to come up with the transportation costs to travel to medical appointments or to pick up
medications. Compounding these issues, sickness related to HIV/AIDS may interfere with
someone’s ability to earn their wages in order to save for transportation costs (Tuller et al.,
2010). Transportation challenges have been especially well documented in rural regions of
Uganda (Bajunirwe et al., 2009; Siedner et al., 2013; Tuller et al., 2010). For populations living
in remote areas, it can be difficult to obtain any form of transportation, especially during heavy
rains which complicates the use of boda bodas (Hardon et al., 2006). In three treatment centers
across urban Kampala, while distance to clinic was not identified as a predictor of nonadherence, travel away from home was mentioned by those on cART as a reason for their lack of
adherence. This suggests that the relationship between adherence and geography may be
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complicated by other aspects of geographic mobility (Byakika-Tusiime et al., 2005; Taylor et al.,
2014).
Geographic mobility has been broached as a predictor of retention in HIV treatment and
care (Taylor et al., 2011, 2014). While transportation constitutes a specific aspect of mobility,
mobility itself may be viewed more broadly, including migration to and from other countries.
The United Nations definition of a mobile population includes those “who move from one place
to another temporarily, seasonally, or permanently for a host of voluntary and/or involuntary
reasons” (International Organization for Migration. & UNAIDS., 2001). As Kampala is the
nation’s economic hub, its job market attracts permanent and temporary workers from across
Uganda, and from other countries. Kampala’s resident population has been estimated to be half
the size of the total population which occupies the city during the day (Nyakaana & Sengendo,
2004). This suggests that the city is subject to unique patterns of geographic mobility, with half
its population constantly in transit.
Mobility is multifaceted, and can thus influence HIV treatment outcomes in several ways:
Frequent travel can result in treatment interruptions due to limited drug supplies (Taylor et al.,
2014). For instance, month-long travel plans can be problematic when HIV-treatment facilities
experiencing drug shortages can only provide two weeks’ supply of ARVs (Oyugi et al., 2007).
Some people on cART actually view mobility as beneficial to HIV treatment, because they
believe the quality of care they will receive will be higher where they are travelling to. However,
mobility is generally seen as an impediment to treatment success (Taylor et al., 2014). Some of
those on cART even skip their medication during travel due to the fear of experiencing sideeffects in transit. Non-disclosure of one’s HIV status can also restrict engagement with care
during travel and at destinations, due to concerns of stigmatization.
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2.5 The social context of HIV treatment in Uganda
One’s social context may either alleviate or increase pressures on those who are already
struggling to adhere to their HIV treatment regimen. In Uganda, notable socioeconomic
challenges which compound difficulties on cART include gender inequality, financial insecurity
and HIV-related stigma (Schulkind, Mbonye, Watts, & Seeley, 2016; Tsai, Bangsberg, Kegeles,
et al., 2013; Tsai, Bangsberg, & Weiser, 2013). Globally, HIV is highly stigmatized. This makes
it challenging for people living with HIV to disclose their status, which can increase populationlevel transmission risks (Tsai, Bangsberg, Kegeles, et al., 2013). Stigma is enacted whereby
individuals are subject to hostility and discrimination based on an attribute they possess which is
deemed shameful. Stigma greatly affects the well-being of people living with HIV, who can
develop internalized stigma if they come to accept their society’s negative view of themselves.
This internalized stigmatization has deleterious effects on their mental health, as well as their
adherence to HIV treatment (Tsai, Bangsberg, & Weiser, 2013). Friends and family may also
experience felt stigma for remaining in connection with someone who has HIV (Takada et al.,
2014; Tsai, Bangsberg, & Weiser, 2013). This can further erode social networks which are
critical for the well-being of people living with HIV as well as their likelihood of success on
treatment (Ncama et al., 2008).
With cART, people living with HIV can manage the symptoms of the infection, making it
easier integrate into society without judgement (Tsai, Bangsberg, Bwana, et al., 2013). However,
those who are unable to disclose their status to their peers and their family experience great
difficulty adhering to treatment in secrecy. Social support has been shown to be of great
importance for people living on cART, particularly in low-income nations such as Uganda. In
this context, a strong support system can help to counter financial hurdles such as food
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insecurity, which is a notable impediment to adherence (Tsai, Bangsberg, Kegeles, et al., 2013).
In contrast, feeling stigmatized in social situations has been shown to cause those on cART to
delay taking their medication or to skip a dose rather than risk being disclosed to their peers
(Ammon et al., 2018). Further, stigmatization interacts with pre-existing vulnerabilities such as
poverty and gendered inequities (Goudge & Ngoma, 2011). Stigma can thus be conceived as a
social process which reproduces existing societal inequalities, thus further marginalizing
disadvantaged groups (Tsai, Bangsberg, & Weiser, 2013).
Gender and HIV/AIDS
Gender inequality is intertwined with stigmatization in Uganda. With the association of
the HIV infection with promiscuity, women often face intensified discrimination (Turmen,
2003). Women are often reluctant to disclose their HIV status due to their fear of intimate partner
violence, which is common in Uganda (Karamagi, Tumwine, Tylleskar, & Heggenhougen,
2006). Existing gender norms characterize women’s expression of sexuality as taboo while
normalizing men who have several sexual partners (Jewkes, Levin, & Penn-Kekana, 2003;
Mburu et al., 2014; Nattrass, 2008). Thus, in cases of HIV transmission, blame may be placed on
women (Petros, Airhihenbuwa, Simbayi, Ramlagan, & Brown, 2006). Sexual coercion and
intimate partner violence also make it difficult for women to refuse sex or advocate for condom
use, thus increasing the risk of HIV infection (Ramjee & Daniels, 2013). These social
inequalities can increase the psychological burden of HIV and make it difficult to openly discuss
the infection and access treatment. Patriarchal views of gender encourage men to assume the role
of the provider, while women are expected to bear children (Goudge, Ngoma, Manderson, &
Schneider, 2009; Mburu et al., 2014). In this context, this frequently results in women’s financial
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dependency on men, which has been shown to undermine self-esteem and treatment adherence
(Goudge & Ngoma, 2011).
Expectations of masculinity can also negatively affect men’s engagement with HIV care,
as the same gender norms which contribute to the oppression of women also dictate how men
should behave in the face of illness (Mburu et al., 2014; Nattrass, 2008). The male identity has
been constructed as strong, powerful, independent and in control, while illness is perceived to be
a sign of weakness, which can discourage men from seeking health services or discussing their
HIV status (Nattrass, 2008; Mburu et al., 2014). Studies in South Africa show that while women
are more vulnerable to HIV, men are less likely to access treatment services (Nattrass, 2008).
The association of masculinity with risk-taking has implications for HIV transmission, as well as
health-seeking behaviors. Men may be less likely to seek counselling and treatment due to the
fear that health workers will advise against risky behaviors such as concurrent partnerships
(Mburu et al., 2014). Thus, both female and male gender norms erode the potential of HIV
treatment initiatives. Social challenges such as gender inequality can thus create an environment
where vulnerable populations are structurally exposed to health disadvantages including higher
HIV prevalence and limited usage of HIV testing facilities. The following section discusses
theoretical approaches to assessing healthcare utilization, taking into consideration the wide
range of factors which impact health.
2.6 Theoretical considerations and approach:
Models of access and utilization of healthcare
Health phenomena have been studied from different angles across countless disciplines,
including biology, sociology as well as geography. Early thinkers understood health as the
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outcome of the simplistic relationship between disease incidence and healthcare provision
(Evans & Stoddart, 1990). Under this linear model of health care utilization, an increase in health
services corresponds directly to a proportionate decrease in illness. Similar to the model of
supply and demand, such conceptions of health fail to consider the social determinants which
influence health and well-being. Rejecting the consideration of health as the absence of disease,
the WHO defines health as “a state of complete physical, mental and social well-being and not
merely the absence of disease or infirmity” (World Health Organization, 2020, p. 1). We have
thus sought to understand health and function as mediated by one’s social and physical
environment and not solely biology (Evans & Stoddart, 1990).
In the late 1970s, the biomedical model of disease which was dominant at the time was
critiqued by Engel (1977) as being overly focussed on the biological processes within the human
body. The biomedical model asserts that medical sciences need not consider issues related to
society and even psychology (Engel, 1977). Today, it is suggested that this model of disease
remains dominant, and that this model continues to devalue the role and the experiences of the
patient (Gilbert & Walker, 2009). This dissertation is intended to contribute to the growing body
of literature which explores the social complexities of HIV and HIV treatment. Treatment
success is contingent on adherence, and adherence has been shown to be heavily influenced by
social, cultural and geographical factors. The biomedical model will thus fall short in identifying
predictors of treatment failure, and a more holistic approach is therefore necessary (Gilbert &
Walker, 2009).
Medical and health geographers have been contributing to the study of HIV/AIDS since
the onset of the epidemic. Geographers began by mapping the spread of the disease, eventually
progressing to the investigation of underlying causes of infection (Rosenberg, 1998). In this
21

dissertation we have employed perspectives in health geography which give importance to the
socio-economic conditions which impact health and well-being. These perspectives have
frequently been employed to understand the spread of the infection and predictors of risk-taking
behaviors which increase the probability of HIV transmission. In this thesis, we have used this
approach to investigate predictors of HIV treatment outcomes (Rosenberg, 1998).
In Chapter 4, the objective was to examine geographical barriers to treatment success,
therefore we employed the model of health service accessibility developed by Andersen (1995).
This model, shown in Figure 1, is intended to represent the relationship between health and
healthcare as multidimensional and systemic. Earlier conceptions of healthcare accessibility
feature linear relations between need and use of health services. The model proposed by
Andersen (1995) explains healthcare as several interrelated feedback loops which include
enabling resources such as attributes of the person’s community (Aday & Andersen, 1974). This
analysis will thus consider demographic variables such as income and relationship status which
may influence engagement with health services. Andersen’s (1995) model also incorporates the
perception of one’s health as a factor which in turn influences health practices and thus the use of
health services. Health perceptions and associated theories were further explored in the second
manuscript.
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Figure 1: Behavioral Model of Health Service Use developed by Andersen (1995)

Chapter 5 addresses the research objective of understanding HIV treatment barriers from the
perspective of people on treatment. Hence, we employed the Health Belief Model (HBM) to
understand adherence behaviors based on the perceptions of those on cART (see Figure 2)
(Hochbaum, Rosenstock, & Kegels, 1952). Explained in detail in Chapter 5, this model builds on
early psychological theories which explained behavioural responses to stimuli. The HBM
incorporates cognitive theory which acknowledges an individual’s capacity for reasoning, in the
face of health challenges (Champion & Skinner, 2008; Rosenstock, Strecher, & Becker, 1988).
The HBM asserts that in addition to stimuli (i.e. punishment or reward), an individuals’ beliefs
motivate their health-related actions. These beliefs are in turn influenced by modifying factors
such one’s socioeconomic status (Champion & Skinner, 2008). In the context of cART
adherence, the model’s key constructs have been adapted as follows, using the guiding format
published by Champion & Skinner (2008):
-

Perceived susceptibility: The extent to which someone on treatment believes they are
susceptible to the effects of HIV if they do not adhere to their treatment regimen.

-

Perceived severity: The perceived gravity of the consequences of poor adherence.
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-

Perceived benefit: The degree to which someone believes they will benefit from strictly
adhering to their treatment.

-

Perceived barriers: The perception of challenges associated with remaining adherent to
treatment.

-

Perceived self-efficacy: The extent to which someone believes they are capable of being
highly adherent to treatment.

Figure 2: Health Belief Model adapted from Champion & Skinner (2008)

2.7 Chapter Summary
In the face of debilitating obstacles such as financial insecurity, people on cART in
Uganda struggle to take life-saving medications. This chapter has shown the individual and
population-level risks of suboptimal adherence, as well as key factors which impact treatment
success. While substantial progress has been made toward the SDGs and the newest targets for
universal HIV treatment coverage, several existing barriers threaten to undermine the enormous
potential of cART programs in Uganda. Geographical barriers have often been identified as a
substantial issue associated with HIV treatment; however, the extent to which geography
compromises treatment success is still unclear. Structural barriers to treatment accessibility also
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exist within the context of socioeconomic processes such as poverty, stigmatization and gender
inequality, which cannot be considered separately. Andersen’s (1995) model of healthcare
utilization and the Health Belief Model are two conceptual frameworks which are frequently
used to examine deficiencies in the public health system and predictors of health-related
behaviours. These two overlapping models of health and healthcare were employed in the
manuscripts found in the following chapters. Andersen’s (1995) model of healthcare accessibility
was used in Chapter 4, which considers the influence of factors such as one’s external
environment and perceived health status on health service utilization (Andersen, 1995). Health
perceptions were further explored in Chapter 5, where we used the Health Belief Model to
analyze predictors of HIV treatment adherence.
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Chapter 3: Research Methodology
3.1 Introduction
This chapter outlines the methodology employed in this dissertation. The chapter begins
with a summary of the study’s context in Uganda, to provide the reader with a broader context in
which to situate our research results. An overview of ontological and epistemological
considerations is provided, in addition to a statement regarding the positionality of the authors.
The proceeding section introduces the study design, including the roles of the research team, the
data collection procedure, and the analytic strategy.
3.2 Study Context
Uganda is a landlocked country located in East Africa, sharing a border with Rwanda,
Tanzania, Kenya, South Sudan and the Democratic Republic of the Congo (Figure 3). Stradling
the equator, the country has a tropical, rainy climate, with two dry seasons (Central Intelligence
Agency, 2020). Kampala, the nation’s rapidly growing capital city, is located towards the south
of the country, near the shores of Lake Victoria (Vermeiren, Van Rompaey, Loopmans,
Serwajja, & Mukwaya, 2012). Kampala had its origins as the royal capital of the Buganda
Kingdom, and as such, the Bagandas are dominant ethnic group (Nkurunziza, 2006). The
dominant religions include Protestant (45.1%), Roman Catholic (39.3%) and Muslim (13.7%).
The most commonly spoken languages include Luganda as well as English, which is the
language officially taught in schools (Atuyambe et al., 2008; Central Intelligence Agency, 2020).
Other local languages spoken within Kampala include Runyankole-Rukiga, and Lusoga.
Kampala has a population estimated at around 1.5 million as of 2014 (Uganda Bureau of
Statistics, 2018a). Kampala city’s neighboring districts include Mukono, Luweero and Wakiso,
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the location of the study site (see Figure 3). Inclusive of the neighboring districts which are often
considered part of the Greater Kampala Metropolitan Area, official population estimates reach
over 4.5 million (Kiggundu & Mukiibi, 2013; Uganda Bureau of Statistics, 2018a; Vermeiren et
al., 2012). As previously mentioned, the city’s population doubles during daytime hours with the
arrival of temporary workers and residents (Nyakaana & Sengendo, 2004). An estimated 60% of
Kampala’s residents live in informal settlements, otherwise known as slums, which are
characterized by high population densities and inadequate infrastructure for health and safety
(Kulabako, Nalubega, Wozei, & Thunvik, 2010).
Within Kampala, 5.1% of females and 7.8% of males are estimated to have completed
secondary school. 63.1% of women in Kampala were employed in 2016, with the largest
proportion (43.3%) working in sales and services. As of 2016, 90.3% of men in Kampala were
employed, with 24.1% in professional, managerial or technical positions and 24.0% working in
sales and services (Uganda Bureau of Statistics & ICF, 2018). The median monthly earnings for
those employed in Kampala was calculated at 300,000 Ugandan shillings (approximately
$112.00 CAD) during the 2016/17 fiscal year. Income estimates in urban areas such as Kampala
are estimated to be over twice as high as earnings in rural regions (Uganda Bureau of Statistics,
2018b).
In Kampala as well as the rest of Uganda, health insurance is uncommon, with 7.6% of
women and 9.9% of men reporting some kind of insurance plan (i.e. employer based, privately
purchased, etc.) (Uganda Bureau of Statistics & ICF, 2018). The majority of medical costs in
Uganda are paid for out-of-pocket. For HIV/AIDS care in particular, cART programs have
received a substantial amount of funding to minimize out-of-pocket payments. However, the
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majority of this funding comes from donor sources (Agaba, 2009; Kwesiga, Zikusooka, &
Ataguba, 2015).
By 2007, cART programs had been established in 140 accredited health facilities,
including regional referral hospitals, district hospitals and district health centers across Uganda
(Hardon et al., 2006). Namely, the Mulago National Referral hospital in central Kampala has
provided HIV treatment services to tens of thousands of people living with HIV. Nongovernmental organizations such as The Aids Support Organization (TASO) and Mildmay
Uganda (MUg) also have locations in Kampala which offer cART (Hardon et al., 2006). The
JCRC is Uganda’s main HIV treatment provider, estimated to have provided treatment to over
200,000 people (Joint Clinical Research Centre, 2019; Poon et al., 2019). In Kampala alone, the
JCRC provides cART to 15-20,000 people living with HIV (Kyeyune et al., 2016, 2013). The
JCRC was one of Uganda’s first HIV treatment centers, established with government support in
response to the escalating HIV/AIDS epidemic in the 1990s. While the JCRC is a private
medical research institute, it provides free ARVs in its public facilities in addition to medications
offered at a cost through its private wing (Hardon et al., 2006).
The study was conducted at the JCRC headquarters which are located approximately
10km from the city center, in the Lubowa suburb of the Wakiso district. This JCRC is accessible
using the main highway called Entebbe road, which travels towards the city center in one
direction and the airport in the other. Uganda’s mass transit system consists mainly of privatelyowned intercity buses, minibuses (also known as matatus) and motorcycle taxis called boda
bodas (Muni et al., 2020; Raynor, 2014). A high volume of vehicles regularly filter through
Kampala, Uganda’s capital city, resulting in traffic jams (Vermeiren et al., 2012). With their
small-sized vehicles called ‘boda bodas’ which can weave through traffic jams and send their
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clients directly to their destination. The ‘matatus’ (shuttle transport) travel consistently along
Entebbe road, and while they generally cost less than ‘boda bodas’, the price may fluctuate.
However, they run on regular routes which often exclude more remote areas.
Features of the study site, such as the configuration of road network and the distribution
of treatment centres, have a great bearing on our research results. There are an incalculable
number of variables which impact HIV treatment success in Kampala, and it is not possible to
account for them all in statistical models or thematic analyses. We have attempted to design our
study to represent the most salient predictors of treatment success. The purpose of this overview
of the study site is to further situate our findings into the local context.

Figure 3: Map of Kampala, Uganda and the location of the JCRC
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3.3 Methodological perspectives
Etic and Emic Perspective:
The factors which prevent and enable an individual to take their mediation are
exceedingly complex. Such complexities are rooted in local belief systems and cultural
constructions of illness which are often misinterpreted by the ‘outsider’ (Bonner & Tolhurst,
2002; Hardon et al., 2006). The primary author’s status as an outsider may present limitations in
terms of the interpretation of the study’s results; however, outsider status can also lend a degree
of objectivity to the study. Still, the ultimate goal of this research is to present the perspectives of
people on HIV treatment in Kampala, therefore the author has endeavored to do so while
acknowledging their own preconceptions and biases.
An etic perspective was adopted during this research, as the main author does not identify
as a part of the community under study. An emic perspective is adopted when the researcher is a
member of the community in question, and an etic perspective is used when the researcher is
considered to be an ‘outsider’ (Naaeke, Grabowski, Linton, & Radford, 2012). The identification
of the researchers’ insider or outsider status is particularly important in qualitative research,
where meaning is recognized to be socially constructed and thus subject to biases. Even in
quantitative research, the researcher is a ‘positioned subject’ who exists relative to the study
participants, makes conscious decisions about the manner in which research is conducted (Baxter
& Eyles, 1997). In this dissertation the primary author strives to remain conscious of their
outsider status and the role that this status plays in knowledge construction. The reader is urged
to interpret the study’s findings bearing in mind the main author’s positionality.
Ontology and epistemology of research design

39

Inevitably, research methods are developed within existing knowledge paradigms, which
guide the way researchers see and understand the world (Phoenix et al., 2013). Philosophical
theories about the nature of reality and knowledge are implicit in any research design, regardless
of the discipline. Where ontology relates to the question of how we conceive of reality,
epistemology relates to the question of what constitutes valid knowledge (Aitken & Valentine,
2014). Research paradigms are composed of ontological and epistemological theories, and they
have not remained constant over time. For instance, the biomedical model of disease which was
dominant in the 20th century is derived from positivist philosophies, as the model contends that it
is purely scientific and apolitical (Goldenberg, 2006). The ontological stance of positivism
asserts that there is one true reality. Positivist epistemology maintains that reality can and must
be objectively measured. This methodology has been criticized as reductionist. Claims that
positivist research can possibly be objective are also often rejected on the basis that such an
approach leads to unintentional biases. Interpretivism, which is found at the opposite end of the
spectrum from positivism, asserts that reality is constructed and cannot be measured However,
this philosophy can create challenges for policy development which often relies on measurable
evidence (Lincoln, Lynham, & Guba, 2011; Phoenix et al., 2013).
Post-positivism, which differs from positivism in its ontological and epistemological
assumptions, emerged as a response to these critiques. Post-positivism works with a similar
notion of one existing reality, but maintains that research cannot fully understand that reality, it
can only approximate it. Post-positivists also acknowledge a degree of subjectivity which is
inseparable from scientific research. Rather, post-positivist researchers strive towards objectivity
while acknowledging their own biases (Lincoln et al., 2011; Phoenix et al., 2013). In this
dissertation, we have adopted a post-positivist approach to Health Geography, with the
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understanding that human experiences are inexplicably complex. We employed mixed research
methods, including surveys as well as semi-structured interviews. Chapter 4 features a study
which attempts to express the relationship between treatment adherence and geography using
statistical measures. In acknowledgement of the short comings of quantitative research methods,
the study found in Chapter 5 serves to represent the lived experiences of those on treatment, with
the incorporation of the participants’ testimonies. The use of qualitative and quantitative methods
has been debated, with the categorization of quantitative research as positivist and qualitative
research as interpretivist. However, this post-positivist study design allows us to gain a broader
understanding of our research problem while maintaining the robustness of findings to inform
policy development (Teye, 2012)
3.4 Study Design
This study evolved from a larger interdisciplinary research project, which has been
progressing for several years under Dr. Arts in the Department of Immunology and Microbiology
at Western University and the Joint Clinical Research Centre (JCRC) in Kampala, Uganda. This
study was deemed necessary to bring a geographic approach to address issues of treatment
accessibility. The lead researchers of this study include representatives of both Western
University and the JCRC, thus ensuring that the interests of the main stakeholders are
represented throughout the research process.
Ethics approval
Ethics approval was obtained from the Institutional Review Board/Research Ethics
Committee (IRB/REC) in Kampala, Uganda, in addition to approval from the non-medical
Research Ethics Board (REB) at the University of Western Ontario in Canada.
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Research Team
At the JCRC, a team of healthcare workers and administrators were assigned to the study
to assist with the field work conducted between May and August 2019. Intake nurses were
responsible for identifying potential participants and inquiring as to whether those identified
were interested in participating in the study. The nurses received training sessions on the
selection criteria and study protocol, and remained in constant contact with the primary
researcher (myself) throughout the data collection period. Luganda-speaking participants were
assisted by one of three JCRC staff members assigned to the project. A graduate student enrolled
in the Master of Management of Applied Sciences (MMASc) Program in Global Health Systems
in Africa, contributed to the practical components of the study. This student was selected for this
study based on their interest and competency in geography and health research. Several
undergraduate students were also selected to work alongside myself at Western University after
the field work was completed. These students assisted with tasks such as data entry and cleaning.
As the main author of this dissertation, I had multiple roles throughout the research
project. Prior to the field work in Kampala, I was responsible for leading the design of the study
and study tools (i.e. questionnaire) and the submission of the ethics application. Upon arrival to
the JCRC, I coordinated our project team, provide training sessions and liaising with the JCRC
staff to ensure that the project was in line with the mission and vision of the clinic and the local
community. When participants were comfortable in English, I conducted interviews and
administered questionnaires. If participants were most comfortable in Luganda, I played a
supporting role while a member of the JCRC staff spoke with the participant. With some
assistance from research assistants, I also completed the data entry, including the transcription of
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English interviews. Lastly, I was primarily responsible for all data analyses. This was conducted
in Canada, along with the writeup of this dissertation.
Study Tools:
Tools used during data collection included the enrollment consent form, the
questionnaire, and the semi-structured interview guide. It should be noted that this thesis is only
a component of a larger research project which is ongoing at the JCRC. Thus, the consent form
details future analyses and a larger sample size than that which is used in this thesis. The
questionnaire was developed to record demographic and geographic variables, travel patterns,
and health/medical history. It also included the Duke Health Profile, a standardized instrument
used to assess health, although the analysis of this data was not the focus of this thesis. The
interview guide was developed to assist the interviewer in the structuring of the semi-structured
interviews, and to maintain consistency. It contains guiding questions as well as probes to use
when responses are unclear or vague. Where the questionnaire required specific and concrete
responses, the interview guide was designed to be flexible, and encourage discussion. All three
study instruments were developed in English by the research team and translated into Luganda
by JCRC staff. The forms in Luganda were verified by the IRB/REC for any translation errors.
The English forms were also reviewed by JCRC staff to ensure they were free of jargon or
phrases which are particular to Canadian English. All three study tools were reviewed and
approved by the ethics committee. The English consent form, questionnaire and interview guide
are included in Appendix A, B and C, respectively.
Data collection
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Within the JCRC, intake nurses identified HIV-positive patients both successfully treated
on first-line cART for three or more years and those who have failed first-line treatment within
two years. Participant selection criteria are illustrated in Figure 4. Treatment failure constitutes a
substantial increase in viral load (≥ 1000 copies/mL) or immune failure as measured by CD4+
cell count. The association of early virological failure with HIV drug resistance lends importance
to the investigation of early years on treatment (Metzner et al., 2009; Ruel et al., 2011). Thus,
our study included those who experienced treatment failure in the first two years of treatment.
Potential participants were provided with a brief overview of the project and an outline of
any associated risks and benefits. Those who expressed interest in participating were asked to
contact the lead researcher. Participants were then guided through a consent form in their
preferred language. As detailed in the consent form, participants were guaranteed the
confidentiality of research results, which was a frequent concern of the participants due to the
sensitive nature of our research topic. It was emphasized that participants were free to withdraw
from the study at any time or to decline to answer any questions with which they were not
comfortable. After thorough briefing, participants were asked to complete the 13-page
questionnaire. In order to minimize the social conformity of responses, participants were also
reminded that we were not looking for any particular answers. Those who completed the
questionnaire were compensated for their time with 20,000 Ugandan shillings (the equivalent of
about $7.00 CAD).
Survey respondents were selected for semi-structured interviews based on key
characteristics and the relevance of their survey responses to the objective of the study, with the
goal of obtaining deeper insight with regards to a diverse range of cases. The interviews, which
were approximately 25 minutes on average, were audio-recorded using a recording device. In
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addition to the consent form, the use of the audio-recording device was explained verbally to
ensure the participant’s consent was fully informed. Both the interview and questionnaire were
completed privately in JCRC’s research wing. Again, participants were reminded of the
confidentiality of the discussion. Interviewers explained their role in the study and emphasized
that their objective was to understand the participant’s experiences without judgement. It was
important to explain the role of the researchers to alleviate any concerns that participants would
face negative repercussions if they spoke of negative health behaviors (i.e. lack of condom use).
This helped to put the participant at ease and to increase the depth of the discussion.

45

Figure 4: Flow chart of study's selection criteria for participants
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Sample size
Treatment failure is categorized as the least probable outcome, compared to treatment
success, as the majority of those on cART generally maintain viral suppression in early years
(Jaffar et al., 2009). Although there is no clear requirement for sample size, the general rule of
thumb suggests 10 cases of the least probable outcome per predictive variable (Peduzzi, Concato,
Kemper, Holford, & Feinstem, 1996). As our statistical models include a maximum of six
independent variables, this suggests a minimum of 60 treatment failure cases. It has been further
suggested that the ratio of 10:1 may even be overly conservative, where sample sizes with a
smaller ratio have produced substantive findings (Vittinghoff & McCulloch, 2007). Still, our
study included a total of 149 participants, with 93 in the treatment success group and 56 in the
treatment failure group, approaching the 10:1 recommendation. A total of 30 participants were
interviewed, with 15 in each of the treatment failure and treatment success groups. Purposive
(non-probability) sampling was employed in the selection of all study participants. Given the
manner in which participants were recruited, the exact questionnaire response rate was difficult
to calculate. It has therefore been omitted from this dissertation.
Data entry and analysis
The interview audio files were uploaded onto a computer and transcribed verbatim,
excluding any mention of the participant’s name. Luganda transcriptions were translated into
English for analysis. Content analysis was conducted using Nvivo version 12, a computer
software package designed for the analysis of qualitative data. Interview transcripts were thus
analyzed for recurring themes and patterns of communication, using manual coding. In Nvivo,
the coding process helps to organize interview themes into a hierarchy of importance. Frequently
mentioned ideas were coded into nodes, and the relative importance of each idea was established
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based on the frequency with which a topic is discussed during the interview. We did not employ
previously defined coding categories, rather the categories were developed based on information
from the transcripts. As such, our content analysis approach was primarily exploratory. We used
inductive reasoning to formulate general conclusions based on our interview transcripts (Hyde,
2000). The content analysis procedure is further elaborated upon in Chapter 5.
Survey data was manually entered into IBM Statistical Package for Social Sciences
(SPSS) Statistics version 25 and cleaned. Data cleaning included the recategorization and
recoding of variables to facilitate statistical analysis. Due to our limited sample size, dropping
cases due to missing data was not recommended. As the questionnaires were completed with the
help of the research team, we were able to maintain a relatively high response rate. In the event
of missing data, values were imputed based on the most frequently occurring response.
The software package Stata 16 was used to conduct the statistical analyses of variables
derived from survey data. Multivariate logistic regression was used to investigate the relationship
between HIV treatment outcomes and social, geographic and demographic variables. We used
logistic regression analysis to predict treatment failure, as well as a measure of adherence. The
key independent variable was the self-reported time taken to reach the clinic. We initially
hypothesized that increasingly substantial geographic barriers would hinder treatment success.
We estimated self-reported travel time to be representative of a key geographic barrier
experienced by those on cART. This portion of the study was mainly confirmative, as we set out
to prove or disprove our hypothesis. Deductive reasoning was used to test existing theories that
geographical barriers have a negative impact on treatment outcomes (Hyde, 2000). Further detail
on regression analyses can be found in Chapter 4.
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Although the extent to which inductive and deductive reasoning was used differs in the
two manuscripts, both papers are rooted in similar ontological and epistemological perspectives.
Our regression analyses serves to provide evidence to support or oppose claims about the impact
of travel time on treatment outcomes. Similarly, content analysis provides a rough estimate of the
challenges which are most important to those on cART. However, conclusions made throughout
both manuscripts do not purport to be definitive by any means.
3.5 Chapter Summary
In efforts to move past reductionist approaches to the study of health and illness, a postpositivist perspective was adopted throughout this research. The primary author’s status as an
outsider offers benefits and drawbacks in terms of the validity of the study. Regardless,
conscious awareness of the researcher’s “outsider” frame of reference is critical for the
interpretation of our results. This chapter has given an overview of the research methods
employed in this mixed methods study, including the logistic regression of treatment outcomes
and content analysis of interview transcripts. Further detail on methodology can be found in
Chapters 4 and 5.
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Chapter 4: Failure is not an Option: Barriers to HIV-1 Treatment Adherence in Kampala,
Uganda
Introduction and Background:
The introduction of combined antiretroviral therapy (cART) has made it possible to slow
the progression of the human immunodeficiency virus type 1 (HIV-1), thereby improving the
health and well-being of millions of HIV-positive individuals (Reda & Biadgilign, 2012). SubSaharan Africa shoulders the majority of the burden of the HIV epidemic, with 1.4 million
people living with HIV in Uganda alone (Lange, Perriens, Kuritzkes, & Zewdie, 2004; UNAIDS,
2018a). Within the last decades, treatment programs have become widespread across the
continent with the assistance of financing organizations such as The US President's Emergency
Plan For AIDS Relief (PEPFAR), Global Fund to Fight AIDS, Tuberculosis and Malaria, as well
as strategic partnerships with pharmaceutical companies and foundations (Hardon et al., 2006;
Reda & Biadgilign, 2012). As a result, it was estimated that 72% of people diagnosed with HIV
in Uganda were on treatment as of 2018 (World Bank, 2018a).
cART consists of several drugs taken in combination to target the virus at various stages
of its life-cycle, in order to prevent replication (Zolopa, 2010). Patients who are successfully
treated on cART are considered to be virally supressed, with an undetectable viral load (i.e. less
than 20 copies of the virus). However, for cART to be most effective, patients must adhere to
strict medication regimens, ideally without missing a single dose (i.e. perfect adherence) (Hardon
et al., 2006). While no standard definition exists for adherence, it generally refers to whether or
not a medication has been taken in a timely manner and at the prescribed dosage. High levels of
adherence (≥95%) to cART are necessary for treatment success as well as the prevention of the
development of drug-resistant strains of HIV (Hardon et al., 2006; Tuller et al., 2010). While
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drug resistance has stabilized in high-income countries, low- to middle-income countries are
experiencing increased prevalence of circulating and transmitted HIV drug resistant strains.
Frequency of treatment failure based on a rebound of circulating HIV and the emergence of drug
resistant HIV following the initiation of first line cART remains higher in Uganda (5%
failure/year of cART) than observed in high income countries, despite Uganda being one of the
first East African countries to implement the scale-up of antiretroviral programs (Author, 2013;
Author et al., 2013; Pham, Wilson, Law, Kelleher, & Zhang, 2014; Author et al., 2019).
While cART adherence reported in African countries has often been shown to surpass
levels of adherence in North American countries, study results tend to vary greatly depending on
the research context. In Uganda, estimates of the proportion of patients who reported optimal
cART adherence ranged from 68% to 98% (Mills et al., 2006). Adherence rates have also been
shown to decline over time in long-standing treatment programs (Nachega et al., 2010). Those
who miss more than one dose of their medication in a week are already at risk of treatment
failure, and thus the development of drug resistance (Hardon et al., 2006). Patients generally
begin on first-line cART (the most effective and low-cost medication), which is often available
through many treatment programs in low-income countries such as Uganda, free of charge.
However, drug-resistant HIV may require treatment with second- or third-line cART which can
be costly, require more treatment monitoring, have greater adverse events, and involve more
complicated treatment regimens (Bacha, Tilahun, & Worku, 2012). Patients experiencing
virological failure in Uganda may therefore have limited access to second- and third-line cART,
highlighting the need for the identification of predictors of treatment failure and barriers to
adherence (Boender et al., 2015; Hardon et al., 2006).
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Frequently cited barriers to adherence include: food security, transportation, stigma, sideeffects, waiting times, forgetfulness, lack of community support, and cost (Byakika-Tusiime et
al., 2005; Hardon et al., 2006; Weiser et al., 2003). It is debated whether sub-optimal adherence
in Uganda can be attributed to difficulties accessing the medication rather than an inability to
follow the drug regimen (the former requiring structural rather than behavioral interventions)
(Crane et al., 2006). Accessibility can refer to spatial and temporal attributes such as the distance
and transit time to the clinic (Andersen, 1995). However, access can also be conceptualized by
examining whether characteristics of the population such as income and social class, create
barriers to obtaining proper healthcare, and thus impacting treatment adherence. The framework
proposed by Andersen (1995) addresses healthcare accessibility by considering a myriad of
factors which affect the accessibility of health services beyond supply and demand. While it is
critical that the population’s needs be met with a proportional supply of health services,
characterization of the population in a given service area helps us to understand factors that
motivate the initial visit to a health facility, as well as the reasons for continued adherence. It is
therefore necessary for attempts at spatial predictions of accessibility to consider the range of
pressures experienced by those on cART, and not just the characteristics of the health delivery
system i.e. the number of facilities (Andersen, 1995; Luo & Qi, 2009).
Studies have presented contradictory evidence as to whether or not the distance to
treatment facilities in Uganda is in fact a significant predictor of treatment failure (Ammon et al.,
2018). Those on cART frequently cite their inability to pay for transport costs as a reason for
non-adherence, yet it is often shown that there is no substantial association between treatment
outcomes and geographical mobility (Billioux et al., 2018; Byakika-Tusiime et al., 2005; Hardon
et al., 2006). The objective of this study is therefore to determine whether geospatial barriers (i.e.
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travel time) have a negative impact on HIV treatment (cART) outcomes in Kampala, Uganda.
Secondly, we sought to identify other predictors of cART adherence and treatment failure. We
tested the hypothesis that those with a greater burden of mobility would experience lower levels
of adherence and therefore be more susceptible to treatment failure, compared to those who
travel minimally, after controlling for demographic characteristics.
Methods
Study Site:
This project was conducted in partnership with the Joint Clinical Research center (JCRC)
in the greater Kampala region, who have provided HIV treatment services for over 200,000
patients in Uganda, in addition to other services such as tuberculosis care and treatment.
Antiretrovirals are available at the JCRC free of charge. The treatment facility is located in the
Wakiso district, approximately 10 kilometers away from Kampala’s city center (see Figure 3).
Kampala is Uganda’s capital city, located in central region of Uganda bordering Lake Victoria
(Vermeiren et al., 2012). As Kampala is found within the Buganda Kingdom, the most
commonly spoken language is Luganda (Brisset-Foucault, 2013). However, the city’s rapid
urban expansion and increased commercial activity has drawn settlers from various regions of
Uganda, with a variety of native languages. Paved roads in Kampala funnel traffic through the
densely populated city, resulting in severe traffic jams (Vermeiren et al., 2012).
Study Design:
Data was collected from patients receiving routine care and treatment from the JCRC,
under an agreement of confidentiality. In-country ethics approval was obtained from the
Institutional Review Board/Research Ethics Committee (IRB/REC) in addition to approval from
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the Research Ethics Board (REB) at the University of Western Ontario in Canada. From the
JCRC’s HIV treatment department, eligible patients who arrived for their regular clinic visits
were asked if they were interested in participating in the study. Patients who expressed interest
were given a consent form in their preferred language (either English or Luganda). Patients who
agreed to participate completed a structured questionnaire specifying demographic, geographic
and behavioral characteristics. As stated in the consent form, participants were reminded that
they are free to withdraw from the study at any time without fear of repercussion. Participants
were also assured that their data would remain confidential. Upon completion of the
questionnaire, participants were compensated for their time and transportation costs.
In order to evaluate predictors of divergent treatment outcomes, the study included two
cohorts of patients: those who had been successfully treated on first line cART for a period of
three years and those who have experienced treatment failure on first-line cART within two
years. All patients receiving cART pass through the same intake department, no matter which
line of treatment they are on, therefore both cohorts were recruited from the same pool of
patients. As treatment failure represents the least frequent treatment outcome, the treatment
success cohort consisted of 93 individuals, while the treatment failure cohort consisted of 56
individuals. Treatment ‘failure’ was determined based on clinical parameters (i.e. detectable viral
load) obtained from the JCRC patient database, and adherence to cART was assessed with
respect to missed appointments and discontinuity of drug regimen (using self-reported data &
JCRC patient logs). Patients’ treatment regimen (i.e. first-line, second-line, etc.) was recorded
using the patient database.
Data and Measurement:
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The focal dependant variable was treatment failure (failure = 1 and success = 0), in
addition to indicators of treatment adherence such as missed doses (yes/missed = 1 and no/never
missed = 0). Adherence was assessed from when the patient was initiated on first-line treatment.
To measure adherence, participants were asked if they have ever 1) missed a dose of their cART
medication, 2) missed an appointment, 3) stopped taking their medication intentionally, and 4)
unable to refill their medication. All four variables were coded as either 1 = yes or 0 = no. All
demographic information was drawn from the study questionnaire, with the exception of age
which was recorded from the patient database. Age was categorized into intervals of
approximately ten years, aggregating the upper and lower limits to ensure the relative equality of
group sizes. Only patients over the age of 18 qualified for the study. Gender and parenthood (i.e.
whether they have children) were also determined based on the participants responses to the
questionnaire. Participants were then asked to identify which income range they correspond to.
Income figures correspond to the amount of Ugandan shillings (UGX) earned per month. As
salaries in Uganda tend to be inconsistent, participants’ responses represent estimates of their
average income (Hardon et al., 2006). Participants originally selected one of five ranges of
income; however, the three higher income ranges were merged due to the small number of
individuals in each group. An income of 100,000 UGX corresponds to approximately $36.00
CAD, and 350,000 UGX corresponds to $126.00 CAD. Participants were categorized as either
below 100,000 UGX per month, over 350,000 UGX, or between 100,000 and 350,000 UGX. An
income of 350,000 UGX is considered to be relatively high in the Ugandan context, accounting
for purchasing power (Wanyenze et al., 2006). Those who identified themselves as unemployed
were aggregated into the category of under 100,000 UGX.
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Participants indicated their current relationship status. Those who reported that they are
single (i.e. never married) were grouped into one category. Those who indicated that they are
currently married or have a boyfriend/girlfriend were grouped into the category “with partner,”
and those who indicated that they were previously married (now either widowed or
separated/divorced) were grouped together. This categorization of relationship status follows the
general method employed by Wanyenze et al. (2006), adjusted slightly to assess the impact of
partnership on adherence, rather than marital status. Finally, patients indicated the time they
spent in transit on the way to the clinic where they receive HIV treatment (JCRC). Original
categories were as follows: 1) less than 10 minutes, 2) 10 to 30 minutes, 3) 30 minutes to one
hour, 4) one to two hours, 5) greater than two hours. This variable was re-categorized to 1) less
than one hour, 2) one to two hours, and 3) greater than two hours, to ensure the adequacy of
group sizes per category for the regression analysis. Accounting for the urban context of
Kampala, travel times were taken into consideration rather than travel distances, as movement
through the city is often restricted due to traffic rather than kilometer distance (Vermeiren et al.,
2012).
Statistical Analysis:
The statistical analysis was conducted in various stages. All survey data was initially
entered into IBM SPSS Statistics 25, and then analyzed using the statistical software package
Stata 16. Descriptive statistics were first calculated for all theoretically relevant demographic and
clinical variables, indicating counts and sample percentages for categorical variables (seen in
Table 1 and Table 4). The mean and standard deviation of viral load was computed, as this
measure is a continuous variable. In Table 2 and Table 5, bivariate logistic regression was used
to assess the influence of each independent variable, including transportation time, on the key
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dependent variables (treatment failure and missing a dose). Lastly, multivariate logistic
regression was conducted (Table 2 and Table 5) to determine the relative influence of transit
time when controlling for demographic variables. We evaluated potential demographic variables
that may influence adherence including family composition, gender, wealth and age. Results
were presented with odds ratios (OR) derived from regression coefficients.
Logistic regression was the most appropriate choice for analysis, as the data satisfies key
assumptions. Both outcome variables are binary (whether or not one failed on treatment, and
whether or not one missed a dose), observations are independent of one-another, and there is no
multicollinearity between independent variables. The study’s sample size approaches the
suggested minimum observation-predictor ratio: A minimum of ten cases representing the least
probable outcome should be included per independent variable (Peng, Lee, & Ingersoll, 2002).
The least probable outcome was treatment failure, with a probability of 0.38. With a total of six
independent variables included in statistical models, the suggested minimum sample size is 158.
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Results:
Table 1: Demographic and health characteristics of treatment failure and treatment
success cohorts
Treatment Success Cohort Treatment Failure Cohort
Covariates
(n=93)
(n=56)
Time to Clinic
Less than one hour
41 (44.09%)
23 (41.07%)
One to two hours
20 (21.51%)
20 (35.71%)
Greater than two hours
32 (34.41%)
13 (23.21%)
Viral Load (copies/ml)
<20 (SD 0)
260,525.93 (SD 840102.75)
Age
18-30
14 (15.05%)
17 (30.36%)
31-40
22 (23.66%)
17 (30.36%)
41-50
34 (36.56%)
8 (14.29%)
51+
23 (24.73%)
14 (25.00%)
Gender
Female
60 (64.52%)
36 (64.29%)
Male
33 (35.48%)
20 (35.71%)
Income (UGX)
<100,000 (including
40 (43.01%)
24 (42.86%)
unemployed)
100,000-350,000
33 (35.48%)
21 (37.50%)
> 350,000
20 (21.51%)
11 (19.64%)
Relationship Status
Single
16 (17.20%)
13 (23.21%)
With Partner
56 (60.22%)
31 (55.36%)
Separated or Widowed
21 (22.58%)
12 (21.43%)
Children
Has children
80 (86.02%)
43 (76.79%)
Does not have children
13 (13.98%)
13 (23.21%)
Mean (SD) or n (%), Sample size = 149.
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As shown in Table 1, all participants in the treatment success cohort have an undetectable
viral load (below 20 copies of viral RNA per ml of plasma) and therefore standard deviation was
zero. This was expected, as anyone who is successful on cART will have suppressed the virus to
the point where it is undetected by standard viral load tests. The mean viral load for the treatment
failure cohort was approximately 260,500 copies of RNA/ml of plasma, with a detectable viral
load classified as >1000 copies/ml. However standard deviation was comparatively high, at
approximately 840,000 (Table 1).
In the sample, the largest proportion of participants fell into the 40-50 year age range.
The mean age for the success cohort was approximately 43 and the mean for the failure cohort
was 40. Although mean ages are similar, the distribution across age categories differs. In the
treatment failure cohort, the 41-50 age range contained the smallest proportion of participants.
However, the largest proportion of the treatment success cohort fell between ages 41-50. The
proportion of males and females is relatively equal in both groups, although the majority of the
sample were women. This was expected as women are both more likely to seek out treatment
and more vulnerable to HIV due to biological and cultural factors (Türmen, 2003; Mills, Beyrer,
Birungi, & Dybul, 2012).
In Table 2, Model 1 assesses the bivariate association between transit time to clinic and
treatment failure, in addition to an analysis of the relationship between demographic variables
(age, gender, income, parenthood and relationship status) and treatment failure. Model 2 in Table
2 assesses the association between transit time and treatment failure when controlling for
demographic variables. In terms of the variables of interest, the treatment failure and success
cohorts seem remarkably similar. The maximum log likelihood for Model 2 (-91.02) barely
increases from the baseline of -98.64 which was calculated for the intercept-only model, with no
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covariates (Peng et al., 2002). A substantial increase in the value of log likelihood would have
hinted at the fit of our model’s coefficients. Both models are weak predictors of treatment
failure, as the only significant association is seen in the 40-50 age range, suggesting that
compared to patients aged 18-30, patients aged 41-50 had a 61% decrease in their probability of
treatment failure.
Table 2: Bivariate (Model 1) and multivariate (Model 2) and
regression of treatment failure (OR)
Covariates
Model 1: OR (SE)
Model 2: OR (SE)
Time to Clinic
Less than one hour
(reference)
One to two hours
1.78 (.73)
1.76 (.77)
Greater than two hours
.72 (.30)
.79 (.37)
Age
18-30
(reference)
31-40
.64 (.30)
.66 (.34)
41-50
.19 (.10)**
.18 (.11)**
51+
.50 (.25)
.50 (.27)
Female
.99 (.35)
.50 (.32)
Relationship Status
Single
(reference)
With Partner
.68 (.30)
.65 (.32)
Separated or Widowed
.70 (.36)
.80 (.45)
Have Children
.54 (.23)
.83 (.44)
Income (UGX)
<100,000
(reference)
100,000-350,000
1.06 (.40)
.99 (.42)
>350,000
.92 (.42)
1.02 (.44)
**p < .01. Sample size = 149. SE: Standard Error.
Model 2 Maximum Log Likelihood: -91.02Model 1 Maximum Log
Likelihood: -96.57
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Table 3: Logistic regression of treatment outcome (bivariate)
Covariates
OR (SE)
Missing doses (unintentionally)
2.10 (.72)*
Missing appointments
1.01 (0.40)
Stopped taking medication intentionally
2.93 (1.75) †
Unable to refill medication
3.71 (2.37)*
†
p < .10. *p < .05. Sample size = 149. SE: Standard Error.
A bivariate analysis of adherence indicators was conducted to gauge their importance as
predictors of treatment failure (Table 3). Expectedly, a lack of adherence was a significant
predicator of treatment failure. Those who miss a dose were more than twice as likely to fail (OR
= 2.10, p < .05). Similarly, those who reported an inability to refill their medication were
approximately 3.7 times more likely to fail treatment (OR = 3.71, p < .05). Those who indicated
that they intentionally stopped taking their medication were also more likely to fail, although this
association was noted with little statistical significance and should thus be interpreted with
caution (OR = 2.93, p < .10). In total, 42% of participants reported having missed at least one
dose of their medication (n=63), the majority of which reflected on periods of low adherence
rather than simply missing one dose. Compared to other measures of adherence, missing a dose
was the most statistically significant predictor of treatment failure (p = .03), and the most
frequently occurring indicator of sub-optimal adherence. This measure was further examined in a
separate logistic regression in order to gauge the influence of our predictor variables on the
likelihood of missing doses.
As shown in Table 4, of those who reported missing doses of cART, over 55% travel
under one hour to reach the treatment facility, with approximately 25% traveling between one
and two hours and 19% of participants traveling over two hours. Of those who reported never
missing doses, approximately 34% travel under one hour, with 28% traveling between one and
two hours and over 38% traveling over two hours to reach the treatment facility. Among both
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those who reported missing and those who reported never missing, the greatest proportion of
participants fell into the low-income employment category (including those who are
unemployed). Amongst those who reported never missing, approximately 48% were either
unemployed or had low-income employment. Approximately 37% of those who reported missing
doses fell into the lowest income category of our sample. Amongst those who reported never
missing, and those who reported missing, approximately 57% and 60% had a partner,
respectively. Additional descriptive statistics for groups reporting missed doses and groups
reporting no missed doses can be seen in Table 4.
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Table 4: Demographic and Health Characteristics of HIV-positive
individuals with self-reported optimal and sub-optimal adherence to ART
Self-reported missed
doses (n=63)
Time to Clinic
Less than one hour
35 (55.56%)
One to two hours
16 (25.40%)
Greater than two
12 (19.05%)
hours
Time to Failure
255.25 (SD 306.51)
(days)
Viral Load
44,845.91 (SD
(copies/ml)
178,132.32)
Age
18-30
20 (31.75%)
31-40
15 (23.81%)
41-50
12 (19.05%)
51+
16 (25.40%)
Gender
Female
39 (61.90%)
Male
24 (38.10%)
Income (UGX)
<100,000 (including 23 (36.51%)
unemployed)
100,000-350,000
23 (36.51%)
> 350,000
17 (26.98%)
Relationship Status
Single
8 (12.70%)
With partner
38 (60.32%)
Separated or
17 (26.98%)
widowed
Children
Has children
46 (73.02%)
Does not have
17 (26.98%)
children
Mean (SD) or n (%), Sample size = 149.
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Self-reported never
missed doses (n=86)
29 (33.72%)
24 (27.91%)
33 (38.37%)
147.55 (SD 255.63)
136,814.19 (SD
676,623.40)
11 (12.79%)
24 (27.91%)
30 (34.88%)
21 (24.42%)
57 (66.28%)
29 (33.72%)
41 (47.67%)
31 (36.05%)
14 (16.28%)
21 (24.42%)
49 (56.98%)
16 (18.60%)

77 (89.53%)
9 (10.47%)

Table 5: Bivariate (Model 1) and multivariate (Model 2) and
regression of missing doses (OR)
Covariates
Model 1: OR (SE) Model 2: OR (SE)
Time to Clinic
Less than one hour
(reference)
One to two hours
.55 (.23)
.40 (.20) †
Greater than two hours .30 (.13)**
.33 (.16)*
Age
18-30
(reference)
31-40
.34 (.17)*
.20 (.12)**
41-50
.22 (.11)**
.18 (.11)**
†
51+
.42 (.21)
.40 (.23)
Female
.83 (.29)
1.42 (.71)
Relationship Status
Single
(reference)
With Partner
2.04 (.95)
4.28 (2.60)*
†
Separated or Widowed 2.79 (1.51)
8.28 (5.76)**
Have Children
3.16 (1.43)*
3.64 (2.24)*
Income (UGX)
<100,000 (including
(reference)
unemployed)
100,000-350,000
1.32 (.50)
1.53 (.70)
†
>350,000
2.16 (.96)
3.82 (2.42)*
†
p < .10. *p < .05. **p < .01.
Sample size = 149. SE: Standard Error.
Model 1 Maximum Log Likelihood: -97.10
Model 2 Maximum Log Likelihood: -83.62

In Table 5, Model 1 presents the association between our predictor variables and
the likelihood of missing doses. Surprisingly, participants who traveled over two hours to get to
the JCRC were approximately 70% less likely to miss a dose relative to those who traveled less
than one hour, both before (OR = 0.30, p < .01) and after (OR = 0.33, p < .05) controlling for
demographic variables (Table 5, Model 2). Controlling for demographic variables, significance
begins to emerge for other categories of transit time: Those who traveled one to two hours to get
to the clinic were also 60% less likely to miss doses compared to those who traveled less than
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one hour (OR = 0.40, p < .10). Therefore, the trend of decreasing probability of missing doses in
those with longer travel times is consistent across transit time categories.
The association between treatment failure and the 41-50 age range holds in the second
analysis predicting missed doses. In the bivariate analysis, those between the ages of 41 and 50
are least likely to miss a dose, compared to the 18-30 age range (OR = 0.18, p < .05). Further,
those in the 31-40 age range are 80% less likely to miss a dose (OR = 0.20, p < .05). Gender
remained unrelated to adherence throughout the analysis. However, relationship status became
increasingly significant when controlling for demographic variables. Those who have a partner
were approximately 4.3 times more likely to miss a dose, compared to their single counterparts
(OR = 4.28, p < .05). This has been previously reported and may be associated with partner
stigma and concerns in sharing HIV infection status (Dlamini et al., 2009). Further, those who
reported having children were more than three times more likely to miss their medication, both
before and after controlling for demographic variables (OR = 3.64, p < .05). Finally, those who
corresponded to the higher-income category of >350,000 were more likely to miss doses
compared to those who make less than 100,000 (including those who are unemployed). The
bivariate regression suggests that high-income individuals are over twice as likely to miss a dose
(OR = 2.16, p < .10), and the association is amplified after controlling for demographic variables
in Table 5. In Table 5, Model 2, high-income patients were nearly 4 times more likely to miss
their medication (OR = 3.82, p < .05).
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Model 2 appears to be the best fit, with a
maximum log likelihood of -83.62, compared to the
baseline value of -101.50 for the intercept-only
model. Akaike’s Information Criterion (AIC), and
Schwarz’s Bayesian Information Criterion (BIC)

Table 6: Akaike’s Information Criterion
(AIC) and Schwarz’s Bayesian Information
Criterion (BIC)
Model
df
AIC
BIC
Null Model
1
204.99 208.00
Model 2
12
191.24 227.28
Model 2 found in Table 5. df: Degrees of
freedom

provide a further indication of the fit of the model (Table 6). AIC decreases by approximately 14,
suggesting that Model 2 is a better fit than the null model. The BIC, however, is more resistant to
change, and suggests a negative difference. It should be noted that these metrics are a function of
the number of model parameters and the sample size. For moderate sample sizes, the BIC tends
to point to the model which is most parsimonious, therefore this metric may not be appropriate
for this study (Burnham & Anderson, 2004).
Discussion:
The key findings of this study are portrayed in Figure 5, which illustrates the relative
predicted probability that a range of individuals would miss a dose of their medication.
Unexpectedly, the person with the lowest probability of missing a dose is predicted to be single,
unemployed (or low income), and live over two hours away from the treatment facility.
Conversely, someone who has a high paying job, a partner, and lives close to the facility is
predicted to have an 80% chance of missing their medication. Across all four types of
individuals, those who live more than two hours away are much less likely to miss a dose,
compared to someone who lives nearby.
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Probability of Missing Doses

0.9
0.8
0.7
0.6
Transit Time
to Clinic

0.5
0.4

<1 hr

0.3

1-2 hrs
> 2 hrs

0.2
0.1
0
Single
Unemployed

Single High
Income

Partner
Unemployed

Partner High
Income

Figure 5: Probability of missing doses for individuals with and without a partner and with and without
employment
Note: Probabilities predicted from Table 5, Model 2. Association between missing doses and
partnership, compared to those who are single (p <.05), high-income employment compared to
unemployed (p <.05). Association between missing doses and time to clinic of one to two hours (p <
.10) and over two hours (p <.05), compared to less than one hour.

Transport time and cost have been identified in the literature as an important barrier for
adherence, although the degree of influence of transit time on cART adherence and treatment
outcomes is not agreed upon (Ammon et al., 2018; Hardon et al., 2006). Those on cART
frequently cite transport cost as a challenge with cART. However, our results suggest that
transportation time may actually have a positive relationship with treatment adherence. The
findings show that those further away from the clinic (at least two hours) were actually less
likely to report missing their medication. This may be explained by confounding factors that
were not accounted for in our models. For instance, those who decide to receive treatment from a
facility far from their home may be more invested in treatment outcomes than those who visit a
treatment facility nearby. In Kampala, the JCRC is considered to be a high-quality treatment
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facility, which guarantees a constant supply of drugs and minimal waiting times. It is possible
that those who plan to get their medication from the JCRC, and are willing to travel hours to get
there, could be more invested in treatment adherence. Another explanation could be that people
prefer to go to clinics further away because of the deep-seated stigma associated with HIV/AIDS
in Uganda (Hardon et al., 2006). Those on cART in Uganda tend to choose treatment facilities
which are isolated from their home community, in order to avoid contact with friends, family and
acquaintances (Hardon et al., 2006). Such encounters put them at a risk of publicizing their HIV
status and thus facing stigmatization and discrimination.
Further, while it was expected that stable relationships and employment would be
positive predictors of adherence, this study’s results show otherwise. This may be attributed to
the influence of stigma in both their work and family lives. Due to the high prevalence and
importance of HIV/AIDS in Uganda, it is assumed that someone who is taking daily medication
must be taking antiretrovirals and is therefore HIV-positive. Those on cART have expressed the
fear of losing their jobs if they are seen taking medication at work (Hardon et al., 2006). They
mention that their employers believe that someone with HIV has a low life-expectancy and is
therefore not worth the investment of resources such as time and money. The fear of stigma in
the workplace pressures individuals to take their medication in secret, which may prevent
someone from taking their medication at the correct time, which is necessary for cART to be
effective (Hardon et al., 2006). This might be even more so the case for those with high-paying
employment, and thus a higher social status. In these cases, there may be an increased perception
of risk if someone is seen taking their medication.
Stigmatization has also been an issue within communities and households (Ammon et
al., 2018). While we expected family and partner support to improve cART adherence, our
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results suggest the reverse. At the family level, a lack of disclosure of one’s HIV status may
result in poor adherence. Status disclosure often results in abandonment and poor treatment by
one’s spouse, thus prompting many of those on cART to secretively take their medication
(Hardon et al., 2006). Those who were either separated or widowed were also more likely to
miss doses compared to their single counterparts. As this study is retrospective, it is possible that
at that the time of failure, these participants were still in a relationship, making them vulnerable
to stigma. Those with children were also more likely to miss doses, which may be attributed to
busier schedules and/or non-disclosure of HIV status.
In general, the degree of discomfort that those on cART feel when taking their
medication in shared spaces may have a substantial influence on their adherence. The effect of
this discomfort may even be additive if someone experiences stigma or discrimination at home as
well as at work. In the context of health geography, Kearns (1993) refers to space as “the local
context of health, disease and social process” (p. 140). By using this approach to health research,
we can understand the interactions between those on cART and the places they frequent. The
level of stigma experienced at home, at work and around health facilities may have a stronger
influence on adherence than the time spent in transit to the clinic. If the fear of status disclosure
is pervasive in the lives of those on cART, structural interventions such as increasing the number
of treatment facilities will not be effective in improving treatment outcomes. In order to improve
the utilization of treatment services, interventions must consider the experiences of the HIVpositive population within their local contexts, as well as the healthcare system itself (Andersen,
1995).
Limitations:
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Variability in measurements of adherence may produce divergent results. For instance,
participants were asked if they have ever missed doses on treatment. However, if a participant
has been on cART for years, it is probable that they have missed at least one dose. As previously
mentioned, those who reported missing doses tended to have experienced a prolonged period of
low adherence, rather than a single dose. Still, self-reported measures of adherence have been
shown to be consistent with more objective measures of adherence (i.e. electronic drug
monitoring) (Author et al., 2004). Regardless, the development of standardized measurements of
adherence will facilitate future analyses. Quantitative studies should take into consideration the
variability of the lived experiences of those on cART. To conduct a comprehensive evaluation of
the relationship between geospatial variables and treatment adherence, quantitative measures of
geographic mobility should be analyzed in conjunction with qualitative measures (i.e. via semistructured interviews with participants). These interviews were conducted with participants as
part of this research project and results will be analyzed in a forthcoming study.
Finally, the study’s moderate sample size must be taken into account in the interpretation
of results. The sample may not be representative of all those in Uganda who are on HIV
treatment. Rather, the study should be considered within the context of Kampala, and at the
JCRC. Our results suggest a degree of internal validity as our measures of adherence were
negatively correlated with treatment success, which is consistent with academic literature
(Hardon et al., 2006; Lange et al., 2004). The study’s sample size of 149 may present certain
limitations in terms of potential statistical significance, however, related studies have used
similar sample sizes and produced meaningful analyses (Mills et al., 2006; Siedner et al., 2013).
Further research is required to increase the study’s sample size and make more definitive
conclusions about barriers faced throughout the city of Kampala.
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Conclusion:
Adherence greater than 95% to cART is necessary for treatment success, and high rates
of adherence are necessary to minimize drug resistance. Although those on cART are highly
motivated to follow their treatment plan, challenges such as stigma undermine their best efforts
to do so. It is therefore crucial that factors influencing adherence are identified and evaluated.
Resource-constrained regions require a context-specific approach to maximize treatment
adherence and combat drug resistance. The identification of barriers to ARV treatment adherence
will provide guidance for future public health initiatives targeting the HIV/AIDS epidemic in
Uganda.
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Chapter 5: “…So that's why we hide, we don't want them to know”— Challenges to
Antiretroviral Therapy Adherence in Kampala, Uganda
Introduction:
Due to the introduction of combination antiretroviral therapy (cART), human
immunodeficiency virus type 1 (HIV-1) is no longer a terminal illness, making it possible for
millions of HIV-positive individuals to live long and healthy lives (Midtbø, Shirima, Skovdal, &
Daniel, 2012; Reda & Biadgilign, 2012). Efforts to combat the HIV epidemic now necessarily
include interventions which target the improvement of treatment services, in addition to the
prevention of disease transmission. Although HIV is now considered a manageable chronic
disease, treatment programs place substantial demands on treatment facilities as well as PLWH.
Antiretroviral therapy inhibits viral replication, thus preventing the progression of the disease
towards acquired immunodeficiency syndrome (AIDS). However, this inhibition of viral
replication, commonly referred to as ‘viral suppression,’ only occurs when cART users are
highly adherent to their treatment regimen. Failure to adhere to cART can result in
immunosuppression, and even the development of drug-resistant HIV (Hardon et al., 2006).
In resource-constrained contexts such as Uganda, access to cART is inequitable and often
inconsistent due to underfunded treatment facilities, travel costs and other systemic barriers
(Gilbert & Walker, 2009; Hardon et al., 2006; Weiser et al., 2003). The importance of the cost of
medication has diminished with the implementation of policies in 2011 which mandate the free
provision of cART in public facilities in Uganda. Funding from financing institutions such as the
Global Fund to Fight AIDS has further alleviated short term financial concerns (Gill, Hamer,
Simon, Thea, & Sabin, 2005). However, common challenges to cART adherence including food
insecurity, accessibility and stigmatization, threaten to undermine the HIV treatment successes
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that have been achieved to date (Gilbert & Walker, 2009; Hardon et al., 2006; Tsai, Bangsberg,
Bwana, et al., 2013).
Consistent with the United Nations targets, Uganda aims to achieve viral suppression in
90% of PLWH by 2020 (where viral suppression equates to under 1000 copies/ml). As of 2018,
the prevalence of viral suppression was reported at 64% (UNAIDS, 2018b). In order to reach this
goal, it is crucial to gain insight into the manner in which affected populations experience HIV
and the resultant economic and societal pressures, as these experiences shape the ability of
PLWH to adhere to treatment. The term adherence is intended to simply address whether or not
such instructions have been followed, rather than place blame on the patient or health care
provider (Hardon et al., 2006). Adherence, previously referred to as ‘compliance,’ can be defined
in this context as the extent to which people on cART follow the instructions given to them by a
physician. Under the concept of adherence, it is acknowledged that patients are independent and
intelligent individuals who play an active role in their medical treatment with their cultural,
psychosocial and political context. While the term compliance tends to focus strictly on medical
objectives such as viral suppression, the notion of adherence as explored in the paper encourages
us to examine the nuanced nature of health-related behaviors as they are influenced by social and
personal challenges (Lutfey & Wishner, 1999).
Theoretical Context
We used theoretical constructs from the Health Belief Model to understand the challenges
to cART adherence in Uganda. In the examination of treatment adherence, the importance of
patients’ perception of health challenges is made evident by the Health Belief Model (HBM)
(Hochbaum et al., 1952). Developed in the 1950s by social psychologists, the HBM seeks to
explain the manner in which individuals respond to health concerns (Champion & Skinner,
84

2008). The model explains that an individual’s actions related to illness and healthcare are
influenced by a set of core beliefs, including one’s perception of susceptibility to illness,
situational severity, and the barriers and benefits of actions. Self-efficacy was later incorporated
into the framework, referring to the degree to which someone believes they have control over
health outcomes (Rosenstock et al., 1988). These core beliefs are in turn influenced by external
variables such as socioeconomic status, education and knowledge. For instance, general
knowledge about HIV/AIDS and treatment is an important determinant of medication adherence
(Reda & Biadgilign, 2012). According to Uganda’s Demographic Health Survey published in
2016, only 48% of women and 49% of men have a comprehensive understanding of HIV
transmission and prevention (Uganda Bureau of Statistics & ICF, 2018).
The HBM is one of the most widely used models for the analysis of treatment adherence
(Gao, Nau, Rosenbluth, Scott, & Woodward, 2000; Vitalis, 2017). The model has been
specifically applied for the study of ART adherence in a variety of contexts including Botswana
and the United States (Gao et al., 2000; Kip, Ehlers, & Van Der Wal, 2009). Generally, the HBM
is used to explain that cART adherence may be influenced by the perception of the severity of
consequences i.e. whether or not someone believes they will become ill if they fail to take their
medication. The framework also informs the importance of understanding the perception of
benefits and barriers to cART adherence. For instance, the cost of transportation to the clinic
may be perceived as an insurmountable barrier by some, and as a necessary burden by others.
Further, the evaluation of self-efficacy is particularly relevant in the context of chronic illnesses
requiring long-term treatment such as cART. Understanding the severity of poor adherence may
not be an effective motivator if the individual does not believe themselves to be capable of
making the substantial lifestyle changes required. The HBM thus provides the underpinning that
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can be used to effectively explain prevailing cultural, social political belief systems associated
with varying degrees of cART adherence in the study context. Specifically, this paper aims to
advance our understanding of the social, geographical and economic complexities which impact
the effectiveness of HIV treatment within the urban context of Kampala, Uganda.
Methodology:
Study Site:
The study took place within the Joint Clinical Research Center (JCRC), a health facility
and research center known for the provision of cART. The JCRC has been operating for over 27
years, providing both public and private HIV treatment services, including first, second, and
third-line treatment. The center is financed by funding agencies such as the Center or Disease
Control and Prevention (CDC), in addition to other funding streams. The JCRC has established
seven regional clinical research centers across the country, with the headquarters located in
Lubowa, a suburb of Kampala, Uganda’s capital city. This study was conducted at the Lubowa
location.
Data Collection:
Ethics approval for the study was obtained in-country via the Institutional Review
Board/Research Ethics Committee (IRB/REC), as well as the Research Ethics Board (REB) at
the University of Western Ontario in Canada. Field work was conducted between May 2019 and
August 2019. Purposive sampling was employed in order to ensure that a range of perspectives
were considered. Participants on arrival at the JCRC, were first contacted by intake nurses who
explained the purpose of the study. Those who expressed interest were then provided with the
contact information for the lead researcher. HIV-positive individuals qualified for the study if
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they had 1) been virally suppressed for at least three years on first-line treatment or 2) failed
first-line treatment with a viral load exceeding 1000 copies/ml, within their first two years on
first-line treatment. Participants were categorized into one of these two groups with reference to
patient charts as well as the digital patient database.
Participants who expressed interest in the study were given a consent form in their
preferred language (either Luganda or English), which detailed the nature of the research. A total
of 30 participants consented to take part in the study, with 15 in the treatment failure group and
15 in the treatment success group. Semi-structured interviews were conducted, using an
interview guide in either English or Luganda which detailed the main questions of interest, in
addition to potential probes to be used by the interviewer. Participants were interviewed by either
JCRC staff (in the case of Luganda speakers) or the research team (in the case of English
speakers). Interviews were audio-recorded and transcribed verbatim.
In addition, participants completed a written questionnaire which included questions on
cART adherence, transportation networks, demographic variables and other relevant topics.
Participants who spoke only Luganda were assisted by the JCRC staff. In the case of both the
semi-structured interview and the questionnaire responses, participants were assured that their
responses would remain confidential, and that their names would not be disclosed. Participants
were compensated for both the interview and the completion of the questionnaire. Throughout
the data collection process, participants were also reminded that their participation is voluntary
and that they are free to withdraw from the study at anytime, without fear of any repercussion.
Analysis:
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Interview transcriptions were uploaded and analyzed using Nvivo 12, a software package
used for qualitative analyses, in order to identify salient themes and common experiences
amongst respondents. The interviews were coded by categorizing statements made by
respondents into various ‘nodes,’ depending on the subject matter discussed. Common nodes
were then grouped together and related to one-another hierarchically. Each interview, or case,
was classified as either ‘Failure’ or ‘Success,’ and analyzed as such. The analytic strategy was
two-fold: to establish broad areas of consensus and differences amongst ‘success’ and ‘failure’
respondents on various topics, and to draw attention to areas of difference between men and
women in terms of cART adherence. Direct quotations from the transcripts are used to illustrate
the themes and contextualize responses from the study participants. The participant's sex,
designation as treatment success or failure, and age are provided at the end of each quotation.
Results:
Sample Characteristics:
The sample was mostly female (63.33%) and employed (70.00%), with a mean age of 41
years old (Table 7). The majority of the sample (66.67%) reported missing doses of their
medication, and 20.00% reported that they intentionally stopped taking their medication at some
point. Participants tend to travel much further to reach the clinic than they do to work, with
approximately 17% of the sample traveling over two hours to reach the JCRC. Over 83% of
respondents have children, with 63.33% of the sample indicating that they are currently in a
relationship.
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Table 7: Demographic and Health Characteristics of
HIV-positive individuals (n=30)
Variable
Treatment outcome
Failure
Success
Gender
Males
Females
Age
50+
40-49
30-39
18-29
Asset ownership
Vehicle
TV
Computer
Radio
Fridge
Running water
Electricity
Livestock
Employed
Hours worked per week (mean)
Monthly Income (UGX)
Less than 100,000 (about 26.00 USD)
100,000 – 350,000
350,000 – 750,000
750,000 – 1,000,000
Over 1,000,000
In school
Have children
Have a partner
Time to clinic
Less than 10 min
10 min – 30 min
30 min – 1 hr
1 hr – 2 hrs
Over 2 hrs
Adherence throughout duration of treatment
Missed one or more appointment(s)
Completely stopped taking medication
Failed to refill medication
Missed taking one or more dose(s)
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Percentage of Sample
50%
50%
36.67%
63.33%
23.33%
26.67%
23.33%
26.67%
10.00%
76.67%
23.33%
60.00%
40.00%
56.67%
86.67%
40.00%
70.00%
63 (SD=21.15)
6.67%
33.33%
20.00%
6.67%
3.33%
3.33%
83.33%
63.33%
6.67%
13.33%
36.67%
26.67%
16.67%
26.67%
20.00%
20.00%
66.67%

A majority of the sample reported a monthly income between 100,000 and 750,000
Ugandan shillings (equivalent to between $26-$198 USD), with 40% of participants making
under $198.00 per month. All participants own a mobile phone and the majority own a television
and radio. Although, not all participants have electricity at home, and just over half have running
water. While some participants are financially well-off, with a laptop and a car and a high-paying
job, some participants live in low-income households. The main themes that emerged from the
analysis were: Knowledge and perception of HIV/AIDS, cART Knowledge and Perception,
Challenges with cART adherence and Patient’s suggestions for improvement.
Knowledge and perception of HIV/AIDS
Within the lifespan of most of the respondents, HIV has progressed from a death sentence
to a chronic disease (Hermann et al., 2009). However, participants reports suggest that
knowledge and attitudes towards HIV have not yet shifted. Many participants use the terms HIV
and AIDS interchangeably, particularly when referring to interactions with community members.
This indicates a lack of differentiation between HIV (the viral infection) and AIDS (the fatal
condition). During the interviews, many participants explained that in their communities the
consideration of “HIV as a death sentence” persists despite the development of medications, as
well as the dominant belief that PLWH “will soon succumb to the illness”.
It is important to note that while the interview questions were centered on HIV treatment,
it emerged from the interviews that testing and transmission were considered to be important
topics for the respondents. Participants suggested that the public’s inadequate understanding of
HIV transmission routes greatly affects how PLWH are perceived in their communities. The
participants were in agreement that many people still hold the belief that HIV can be transmitted
through saliva (i.e. sharing dishes), as mentioned in the following quotation:
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If they get to know that you are sick, they may even refuse to eat on the same plate you
have eaten from. – (Female, Treatment Success Group, Age 28)
A participant offered the insight that this lack of HIV knowledge was the result of family
members’ low level of educational attainment. Another respondent echoed this sentiment,
suggesting that misconceptions about HIV transmission can be attributed to illiteracy. This
participant explained that although they “weren’t the first in their family to be diagnosed with
HIV, family members were reluctant to change their understanding of the illness”. Some
participants also explained that some community members still believe that people contract HIV
as a result of “bad behaviour or low social status”. Overall, several interviewees talked about the
persistent misconception as to whether HIV is a disease or the result of witchcraft. A respondent
reported experiencing the passing of a family member with HIV whose death was attributed to
witchcraft. They emphasized that such cultural beliefs and misconceptions still prevent some
people from seeking out treatment:
Some people still think that HIV can be sent to you through bewitching. You may find
that someone has HIV but they are just in bed thinking that someone has bewitched them
because they have land issues, yet they are HIV positive.
– (Female, Treatment Success Group, Age 29)
The study’s participants also spoke of the discrepancy between the willingness of men and
women to go for testing. Several female respondents described the reluctance of men to do HIV
tests, often pointing to their partner as an example. Approximately 63% of the study sample were
female, supporting the gendered nature of both the testing and treatment and of HIV. Still,
several of the study’s participants noted that they discovered they were HIV positive because
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they were pregnant and made to undergo tests. Other male and female participants indicated that
they only got tested after becoming seriously ill, or after other treatments (i.e. malaria
medication) were not working.
In most villages, even in the city, women get tested. We do get tested because when you
get pregnant the first thing they do is test and the man, he cannot escort you. You go there
alone, and when you find out that you are HIV positive, you cannot go back and tell your
husband you went and tested HIV positive, you cannot. You will wait for his time to go
get tested, and he won’t go, and then he will die. Here, women we get tested, but men in
Uganda don’t, they fear. – (Female, Treatment Success Group, Age 36)
Reportedly, through the ‘test and treat’ approach, Uganda has been making efforts to encourage
the general public to get tested and to immediately initiate those diagnosed with HIV on cART.
However, public knowledge and perceptions about cART remain unclear.
cART Knowledge and Perception
Some participants explained that community members are gradually beginning to
understand that treatment can help those diagnosed with HIV. They suggested that people “have
realized when they take the drugs, they can live longer.” However, participants emphasized that
many community members still do not understand that “it is now possible to live with HIV, if
you are taking cART”. Several participants talked about how in their communities, people still
believe that “taking the medication itself is what will kill them or make them ill,” while other
participants mentioned that some people believe that if you have HIV, you will die regardless of
the medication you are taking. Some participants reported that at times, within the local
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community it is believed that there are particular drugs which when prescribed to someone, are
meant to kill them:
If you go to the clinic and they give you that particular drug [second-line medication],
people think they are trying to kill you, because they think you are spreading the virus. So
people back there [in the village], when they are changed to this particular medication,
they just stop taking it. – (Male, Treatment Success Group, Age 41)
Further, many participants talked about community members who believed in alternative cures
for HIV, including herbs, witchcraft and prayer. A participant agreed that she had also believed
she could be cured through prayers, but later decided to begin cART. These perceptions were
reinforced by other respondents as indicated in the comment below.
There are some who are dissuaded by friends that tell them to go to pastors and Sheiks to
pray for them to heal, others to go to shrines…others prefer traditional herbs only to find
that it doesn’t work and yet now it’s too late to get treatment. – (Female, Treatment
Success Group, Age 44)
Despite the existing misconceptions about HIV, most participants acknowledged that there is no
cure for HIV, and that cART does not eliminate the virus completely, rather it prevents it from
multiplying. Although, one participant did suggest that if you take your medication well, the
virus can disappear.
Somebody even told me that if you really take it [cART] every day, that in the future, the
time can even come when you are totally at zero [viral load]. So I don't know if it was
true or she just wanted to console me, but she said that it's good to take [cART]. You may
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reach a time where the virus completely disappears from your body. – (Female,
Treatment Failure Group, Age 58)
Most respondents explained that cART can allow you to function normally by suppressing the
virus. However, many respondents alluded to having had a lower understanding when they first
started treatment. Participants often reported experiencing difficulties following their treatment
regimen due in part to an incomplete understanding of the level of adherence necessary.
With regards to what happens when someone taking cART misses a dose, every
participant explained that this would negatively affect their health. The extent of the negative
effect did vary noticeably, with some participants suggesting that you would become ill after
missing about a week, and others stating that you would die immediately. Many participants
specifically mentioned that missing doses could render the treatment ineffective (due to drug
resistance). Several others mentioned that the virus would become even stronger than when you
began on treatment:
Well, the virus proves to us that it is very intelligent. Every time you miss, it may adapt
to the drugs within the missed gaps, making it resist medication. – (Male, Treatment
Failure Group, Age 66)
The research also sought to explore participants’ level of understanding of the term ‘adherence,’
as it applies to their cART regimen. When prompted to define the concept, nearly all participants
emphasized the importance of not only taking your medication daily, but taking it at the same
time every day.
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Good adherence is taking your drugs daily at the right time such as seven o’clock. Or if
it’s eight instead, let it be eight and stick to it. – (Female, Treatment Success Group, Age
50)
Here the notion of having an established routine is crucial. One participant boasts that taking
their medication is akin to brushing ones teeth. Several participants also specifically stated that
showing up to clinic appointments is a part of good adherence.
Challenges with cART adherence
Participants elaborated upon various challenges associated with cART adherence,
including the burden of the drug regimen, side effects, food insecurity, accessibility and stigma.
Burden of Drug Regimen
One of the principle challenges associated with cART is the burden of the drug regimen
as the treatment is a lifelong commitment and PLWH must take several pills daily. Most of the
study’s participants reported struggling with side effects, the timing of medication and/or the size
and number of pills. Many respondents explained their aversion to swallowing medication, with
many participants specifically mentioning that it is the size of the pills which makes it difficult to
swallow. Participants often spoke of medication side effects they experienced at some point on
their treatment regimen. Side effects mentioned included dizziness, weakness, nausea and
vomiting, among others. Often, participants explained that side effects only occurred when they
were first initiated on cART, or when they were taking the medication on an empty stomach.
Food Insecurity and Finance
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Although the introduction of cART treatment programs which offer the medication free
of charge at public facilities has taken away the cost of the drugs as a significant barrier, several
participants raised issues related to food and financial insecurity. A respondent commented on
how food insecurity can influence someone’s adherence to cART:
Some people don’t take their pills due to absence of food as it can cause bad side effects
such as nausea. This happened to me as well, but ever since I learnt that I have to eat
before I take the medication, I no longer get those effects. – (Female, Treatment Failure
Group, Age 45)
In this study context, food security goes hand in hand with financial security. Those who
reported financial insecurity discussed how this affects cART adherence primarily due to the
need to take the medication after having eaten.
With that medication, your family must be kind of well-off, and support you with food.
Sometimes at home I didn’t have anything to eat but I decided to take the medication and
deal with the side effects, but there are persons who are doing worse than me. You must
have a source of food and good sanitation at home. – (Male, Treatment Success group,
Age 27)
The need for proper nutrition and clean drinking water was mentioned by most participants, who
emphasized the debilitating side effects which occur if the medication is taken on an empty
stomach. Approximately 43% of our sample reported that they do not have access to running
water, despite Kampala’s rapid urbanization and infrastructure development (Vermeiren et al.,
2012). Discussions surrounding food insecurity were slightly more extensive within the
treatment failure group, compared to the treatment success group.
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Despite difficulties paying for daily meals, some participants opt to avoid public
treatment facilities and pay for their medication instead. Some respondents reported the
motivation to obtain treatment from private clinics due to the perceived sense of privacy offered
at such places, and the quality of services, among other reasons. Participants who began
treatment from a private clinic reported missing several doses of medication due to the cost of
the drugs.
I thought if I could economize the drugs, I’d take it today and tomorrow I wouldn’t.
Mainly, by doing that, I would prolong the drugs to last me for like a month. I thought
that would help me. – (Female, Treatment Failure Group, Age 54)
Thus, even with the provision of free ARVs, costs associated with HIV-treatment remain a
burden. In addition to the cost of regular meals, people on cART must pay for transport to their
medical appointments and to pick up their medications.
Transport and Travel
Overall, participants agreed that transportation and travel related to cART has been a
challenge, especially the time it takes to travel to the clinic and the cost travel. One participant
pointed to accessibility as the biggest challenge:
The main challenge is access, to the proper medication, and to the quickest medication.
Someone might be on ARVs, getting the medication far from where they stay, and you
might find that sometimes they miss their appointment, which is so bad for the treatment.
– (Male, Treatment Success, Age 37)
Popular modes of transportation typically include privately operated buses that run within the
city of Kampala. Motorcycle taxis are also often used to travel to destinations where the buses
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don’t reach. The majority of participants use the buses as well as the motorcycles to reach the
clinic, apart from the few respondents who have access to their own vehicles. As the buses run
along Entebbe road and are less costly than the motorcycles, it is common to use a motorcycle to
reach the bus park, and board a bus to the clinic.
You might find that someone traveling to that health center, will have to pay like 10,000
[Ugandan shillings] for transport. And you can use 10,000 shillings for a daily meal, so if
the medication was available at the village center, it would cost only 2,000 shillings to
access the medication, so I think it would be easier. – (Male, Treatment Success, Age 37)
Due to the heavy traffic which accumulates along Kampala’s main roads, participants indicated
that it takes several hours to reach the JCRC, obliging clients to take the day off work on the day
of their appointments, which may result in an additional loss of income.
Despite issues with transportation, participants still acknowledge the importance of
traveling to get their medication, as it is necessary for their health. However, issues of travel and
transport are further complicated by the persistent stigmatization of PLWH.
Stigmatization
The stigmatization of HIV-positive individuals creates challenges which exacerbate all
other barriers to treatment adherence. All participants frequently emphasized the negative effects
of stigma on their daily lives, whether at work, at home or in transit. A respondent described his
experience of considerable stigmatization and discrimination even within his household, which
eventually forced him to leave home and live elsewhere.
So I was discriminated by my stepmother, who made my [HIV] stigma rise to a level that
I couldn’t even imagine. So I decided to quit taking my drugs … My stepmother would
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isolate my dishes, fork, plate, cup, basin, everything, as if I was in the ICU! – (Male,
Treatment Success Group, Age 27)
Both the success and failure groups of participants spoke at a length about the effects of stigma.
Stigma seemed to have a direct relationship to adherence, as people on cART feel they must take
their medication without being seen, which is increasingly difficult when they are expected to
take several pills per day. In the context of Uganda, it is uncommon for someone to be taking
daily medication. Thus, if someone takes a pill in public, it is often assumed that they are taking
medication for HIV. Due to the taboo associated with the illness, PLWH fear disclosure of their
status.
Some people are negative [towards us], others are positive. There are people who talk
badly about HIV patients. Some people, you find them talking badly about us… so that’s
why we hide, we don’t want them to know our HIV status. – (Female, Treatment Failure
Group, Age 42)
Participants mentioned that they intentionally chose a clinic far from their home so that they
won’t be seen picking up their medication. Participants agreed that locating treatment facilities
near their homes would not be favorable, as they would not like to be seen going into treatment
facilities in their home communities. Several participants also explained that simply carrying the
medication alone poses the risk of exposing their status.
The workers especially, people who work in distant places, they say they fear moving
with the drug because they don't want [their status] to be disclosed … So you find the
time can come when they are scheduled to take their medication but they are traveling to
work, so they miss [taking] the medication. – (Female, Treatment Failure Group, Age 42)

99

Many participants fear to disclose their status, and experience great difficulty in taking their
medication when they are constantly surrounded by people. Many of the respondents explained
their fear that their children would discover their HIV status and face stigma at school or develop
the worry of losing their parents. As 83% of respondents also have children, participants often
struggle to their medication in secrecy. A similar reluctance was conveyed about disclosure to
other family members such as parents or siblings. Some participants are reluctant to disclose
their status because they don’t want to be perceived negatively, and others don’t want their
family to think they are dying (a lasting misconception of HIV/AIDS). While some participants
proudly mention the support they receive from their relatives, many others don’t feel comfortable
taking their medication at home or telling their families that they are going to a medical
appointment.
Due to pervasive stigma within their communities, many respondents struggle to disclose
their status to their partners. The majority of participants were either presently or previously in a
relationship, with 63% reporting that they currently have a partner. Respondents in our sample
who are single similarly expressed frustration at the negative reaction they receive when
disclosing their status to potential partners, and one participant suggested that it is best to remain
single.
A participant reported that they currently have not disclosed their status to their partner,
and other participants reported instances in the past where they hid their HIV status from their
partner. This was suggested to be a greater challenge among women, who face more serious
repercussions if their partner discover they are HIV positive. Women often fear that their partner
will leave them or react violently. As indicated in following comment, respondents tend to avoid
status disclosure for fear of repercussions.
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I hide my HIV status because if I tell my husband to come and get tested and they find
him to be HIV negative when I’m HIV positive, definitely we are going to separate
because his family is going to be like ‘why are you with that woman’? They would say
my sickness would affect him. So [if he finds out] he is going to hate me or he’s going to
chuck me, after chucking me I’d hate myself and say ha! Now what am I doing? Let me
die, because women we need support from men. -5166 (Female, Treatment Success
Group, Age 36)
Within our sample, employed respondents reportedly spend an average of 63 hours per week at
work. Unfortunately, some respondents reported marked discrimination from employers and
colleagues. Several respondents were fired from their jobs because their employer discovered
their HIV-status. When participants openly took their medication or asked for time off to attend
their appointments, people within their workplace would then learn that they are HIV-positive.
…out there the world perceives people [with HIV] differently. In my first job, I was
stigmatized, I would say… My boss found out that I was sick, so I was chased away from
work. So if you get such cases [where someone is fired from their job]—and there are
many out there by the way—someone cannot easily move on with their lives. – (Female,
Treatment Failure Group, Age 29)
Despite long hours spent at work, those employed often fear taking their medication at work,
further complicating their adherence schedule. The respondents explained that much of the
population in Uganda still view HIV as a death sentence, and employers often hold similar
beliefs. According the participants, employers think that someone who is HIV positive is not
worth an investment of time and capital because of the incorrect presumption that such a person
will soon succumb to the illness. Due to this stigmatization within the workplace, many
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participants reported a fear of being seen with medication at work, and a reluctance to disclose
their HIV status to their colleagues.
Patients’ suggestions for improving cART adherence
Participants discussed at a length on what they thought might improve cART adherence
and accessibility, from their perspectives. In general, participants were satisfied with the services
offered at the JCRC. When asked what would improve treatment accessibility across Kampala,
they suggested that the JCRC should open more branches across Uganda. There were also many
requests for an increase in the quality of treatment facilities, and not just the number.
Specifically, respondents valued the care and friendliness of health service workers. They often
explained that positive interactions with health service workers encouraged them to adhere to
their treatment regimen. As many participants gained a lot of clarity on the subject of adherence
through counselling sessions, they suggested that this service should be increased within the
JCRC and at other facilities.
The counsellors should actually encourage the patients and talk to them, because when
they talked to me, I adjusted the time I am scheduled to take my medicine. That is what
worked for me. What works is when the counsellors talk to you, street talk, hip talk… to
encourage you, not shout at you. Because when they shout at someone, they’ll never take
their medicine. Even me, when someone shouts at me, I can even leave the medicine
there and not take it. – (Female, Treatment Failure Group, Age 36)
Many participants also highlighted the need for government support, with one respondent
specifically concerned about the overreliance of the healthcare system on donor funding. Others
requested government support in the form of job security, health programs and increases in the
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quality of treatment services. It was often mentioned that the best way to increase accessibility to
treatment is to improve upon the general public’s knowledge of HIV and HIV treatment.
Participants suggested various methods for accomplishing this objective, including sensitization
via television, radio, social media, church leaders and advocacy through local parishes. The use
of social media was particularly recommended, since Uganda has a strong social media culture.
Specifically, it was requested that information about ARVs should be expressed in layman’s
terms so that the population can understand the particularities of the medication regardless of
their educational background and mother tongue.
Not everyone understands all the ifs and buts about HIV treatment, because it is a
science, and to some extent it is not localized in our language so that everyone can
understand. Even if I did go to school, I still might not understand. So to some extent, not
everyone has someone to explain the science and break it down … so some of them
understand, but some of them do not. – (Female, Treatment Success Group, Age 24)
The value of quality healthcare services was made evident by the study respondents, who
emphasized the importance of knowledge translation to patients and within their communities. In
addition to the burden of a strict medication regimen, those on cART must navigate a social
context which is still unfamiliar with HIV treatment. A summary of the common themes
discussed during semi-structured interviews is provided on Table 8.
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Table 8: Common themes discussed during semi-structured interviews (n=30)
Thematic Coding: Number of participants (number of mentions)
HIV/AIDS knowledge
Testing: 12 (39)
Got tested because they were ill
Got tested because they were pregnant
Men are reluctant to test
People (in general) don’t want to get tested
Transmission: 14 (24)
People think HIV is caused by witchcraft
People think you can get HIV by sharing dishes
Guilt associated with HIV transmission
Confusion about modes of transmission
cART Knowledge/Perception
Community’s perception: 26 (76)
People don’t understand
People are beginning to understand
People think…
HIV is still a death sentence
cART will kill you
You will die even if you take cART
There are alternative treatments
Participant’s understanding: 30 (156)
cART…
Allows you to live
Cannot cure
Fights the virus to weaken it
Reduces symptoms
Decreases the viral load
Makes the virus dormant
Consequence of low adherence: 28 (78)
If you miss…
You become ill/your immune system weakens
The medication will stop working
The virus becomes stronger
You will die
Adherence definition: 27 (58)
Take cART at the same time every day
Keep appointments
Challenges with cART adherence: 30 (661)
Behavioural characteristics: 20 (25)
People miss because they are…
Forgetful
Lazy/complacent
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Careless/negligent
Hopeless
Uncommitted
Burden of drug regimen: 27 (152)
The pills are too big
Timing is difficult
Symptoms and side effects are intolerable
Food security and finance: 25 (86)
Need to take medication with food/water
Cost of drugs is a burden
Financial insecurity is an issue
Health service deficiencies: 20 (30)
Drugs not available
Waiting time used to be an issue
Waiting times are long
Waiting times are reasonable
Transport and travel challenges: 27 (64)
Cost of transport is too much
Clinic is too far
There is too much traffic
Transport is not an important barrier
Frequent travel is a barrier
Stigmatization: 30 (272)
Intentionally go to clinic far from home
Fear of being seen at clinic
Fear of being seen taking medication
Negative perception of PLWH
Stigma at work
Stigma at home/with family
Stigma with friends
Stigma with partner
Stigma is not an important barrier
Participant Suggestions: 27 (103)
Increased advertisement and sensitization
Increase the number of clinics
Increase availability of drugs
Increased counselling
Drug development
Need for government support
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Discussion and Conclusion:
Overall, the findings from this study reveal that there are several persistent challenges to
cART adherence. Although the study’s participants demonstrated a relatively thorough
understanding of the illness at the time of the interviews, their in-depth comprehension reflects
the efforts of years of counselling and personal experience with cART. A low understanding of
cART in early stages of treatment can result in treatment failure due to low adherence, with longterm implications for drug resistance and treatment success. Further, the level of knowledge
alluded to within the general public was lacking. This low level of knowledge of HIV is
consistent with studies based in Malawi which demonstrate the persistence of misconceptions
surrounding HIV, decades after the peak of the epidemic (Antabe, Sano, Anfaara, & Luginaah,
2020; Sano et al., 2016). Misconceptions about cART play a formative role in the perception of
control over treatment outcomes. Personal beliefs that HIV is the result of witchcraft or that it
can be cured by religion may negate any willingness to adhere to treatment. Further, PLWH
develop normative beliefs based on their community’s consensus on treatment options. For
instance, internalized beliefs that HIV is a death sentence may delay or discourage people from
starting treatment. Knowledge levels amongst community members thus have a wide-reaching
effect, with the potential to prevent or encourage positive adherence behaviors (Champion &
Skinner, 2008).
Emerging from the findings here is the fact that after several decades of the HIV
epidemic, stigma has remained deep-seated this study context. The stigmatization of PLWH was
one of the most salient themes which emerged in relation to adherence. A growing body of
evidence suggests that stigma in sub-Saharan African countries has a considerable impact on the
likelihood of missing doses of ARVs (Dlamini et al., 2009). Stigma was expected to decrease as
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the public became increasingly aware of existing treatment options and medical advancement.
However, there is evidence to suggest that HIV stigma may even be increasing (Chan et al.,
2015; Maughan-Brown, 2010). Consequently, the perceived stigmatization (whether warranted
or unfounded) reported has a serious impact on adherence behaviors, whereby people choose to
go to clinics which are located far away from their homes in order to avoid being seen accessing
treatment centres.
Consistent with previous work by Turmen (2003), although stigmatization affects all
genders, it is seen as having a disproportionate impact on women, particularly in the context of
intimate relationships. HIV is considered to be a gendered illness, as women are more at risk to
infection due to biology as well as social, cultural and economic factors. In patriarchal societies
which often dominate regions in sub-Saharan Africa, women are unable to play an active role in
decision-making. For example, violence and forced sexual activity can affect women’s ability to
exercise preventative measures (Ramjee & Daniels, 2013; Turmen, 2003). Women who became
widowed due the HIV/AIDS epidemic also face extraordinary challenges as they have to take
care of their families in the context of sociocultural issues which tend to be made worse by
stigma (Luginaah, Elkins, Maticka-Tyndale, Landry, & Mathui, 2005). This study’s results
echoed the effect of gender disparities on experiences with HIV treatment. During the
interviews, participants described challenges faced by women such as violence in response to
HIV status disclosure. Although women are affected disproportionately, both male and female
gender norms play a role in undermining efforts to combat the HIV epidemic. As alluded to by
the study’s participants, a greater number of women seek out testing and treatment in Uganda,
compared to men (Uganda Bureau of Statistics & ICF, 2018). Some studies in sub-Saharan
Africa suggest that women are more comfortable in a clinical setting than men, and that seeking
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out medical care can be viewed as a sign of weakness for men (Shand, Thomson-de Boor, van
den Berg, Peacock, & Pascoe, 2014; Treves-Kagan et al., 2017). The gendered nature of HIV
must therefore be considered in the planning and implementation of treatment programs.
In the sub-Saharan African cultures, communal living and close family ties are common
and in most cases an expectation (Baskind & Birbeck, 2005). Hence, most participants have
strong social networks, which are supposed to contribute positively to their quality of life. Yet, in
addition to challenges faced in intimate relationships, PLWH can also experience difficulties
amongst friends and relatives. Positive support from friends, family and community members
can increase adherence to treatment and improve the lives of those living with HIV (Ncama et
al., 2008). However, due to the fear of judgement and social ostracization, those living with HIV
are often reluctant to disclose their status to the people around them. Consequently, friends and
family members who surround PLWH in some cases are frequently unaware of their HIV status,
thereby forcing people on cART to take their medication in secrecy. This fear of status disclosure
adds another barrier thus resulting in low adherence, as participants struggle to find an
appropriate time and place to take their medication.
The secrecy that patients must live under has led to a situation where they must go to
clinics located very far from where they live to access cART. Hence, travel and geographic
mobility influence HIV treatment in two main ways. Firstly, frequent or extended travel can
make it challenging to adhere to a regular treatment schedule and to carry the necessary stock of
medication, particularly considering the country’s drug shortages (Hardon et al., 2006).
Secondly, concerns of stigmatization in transit and at the destination can result in a reluctance to
take medication (Taylor et al., 2014). Ultimately, the reason some people would forgo the
convenience of traveling to a nearby clinic is to retrieve medication from a distant community
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where they will not be recognized. These findings are consistent with studies based in South
Africa, the Dominican Republic, and the United States, whereby the fear of stigma in home
communities has pressured people on cART to seek treatment from farther health facilities
(Mills, 2006; Taylor et al., 2014). Clinics such as the JCRC have a reputation for being HIV
treatment facilities and providing services to PLWH. Those who visit the clinic are cognisant of
this reputation and prefer to travel outside of their home community. Given the fact that
participants frequently opted for farther away treatment facilities, it is interesting that some
participants called for more treatment facilities to ease the challenges they face when trying to
access cART. Such facilities may only end up helping to redistribute those on cART but may not
necessarily ease transportation challenges unless the stigma of HIV improves.
As we attempt to untangle the relationship between accessibility and treatment success,
social processes such as stigmatization in public places must be considered. Social support
continues to be important for overall health and well-being. However, efforts towards public
sensitization can help to create social settings which allow cART users to take their medication
without fear of judgement. As requested by the study’s participants, the use of tools such as
social media can improve education surrounding HIV and cART, and inform the population
about the treatment options available. PLWH in Uganda are burdened by multiple overlapping
challenges which exacerbate one another. Challenges such as food insecurity, stigma,
transportation, and financial insecurity cannot be considered individually, as they are deeply
embedded in the fabric of society. As per the Health Belief Model, the perception of such
barriers should be viewed as competing with the perceived benefits of treatment. Knowledge of
HIV/AIDS and cART is often incomplete and muddled by social biases; therefore, treatment
success hinges on the health beliefs which motivate the behavior of PLWH.
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Chapter 6: Summary and Conclusions
6.1 Introduction
This study’s research objectives are united by the common goal of identifying and
evaluating challenges associated with HIV treatment in the context of Kampala, Uganda. Each
objective was approached using appropriate research methodology, in order to contribute the
overarching goal of this dissertation. The following section will summarize the key findings of
each manuscript as they relate to our research questions and hypothesis. The chapter will then
examine how the research objectives intertwine, followed by a summary of the implications of
this research for policy development and future research.
6.2 Discussion of key findings
The following research questions were addressed in the first manuscript found in Chapter
4: Failure is not an Option: Barriers to HIV Treatment Adherence in Kampala, Uganda.
Research question (1):
Do geographical barriers such as time spent traveling to the clinic have a negative impact on
treatment outcomes in the context of Kampala, Uganda?
Research question (2):
What is the impact of socio-economic variables such as income on HIV treatment outcomes?
We hypothesized that those with a greater burden of mobility will experience lower levels
of adherence and therefore be more susceptible to treatment failure, compared to those who
travel minimally, after controlling for demographic characteristics. Our findings from Chapter 4
surprisingly contradictory, suggesting that those who traveled the longest distances to reach the
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clinic reported the highest adherence. This association remained true after controlling for
demographic variables. Many quantitative studies have failed to establish a statistically
significant association between geographic variables and treatment success (Billioux et al., 2018;
Byakika-Tusiime et al., 2005). The results from this research actually showed the reverse,
reporting a statistically significant negative relationship between the distance travelled to the
clinic and the likelihood of reporting missed doses of medication. Although geographical barriers
are often identified as an obvious impediment to treatment adherence, the literature which has
sought to evaluate this association has been divisive (Hardon et al., 2006; Lankowski et al.,
2014; Tuller et al., 2010).
Our results can potentially be explained by the interaction of geographic variables with
extraneous variables which were not accounted for in our models. Although we accounted for
basic socioeconomic and demographic factors, there may be aspects of the social context in
Kampala which further complicate the relationship between geography and treatment success.
The unique geographical position of the JCRC, which is far from the city center but still within
the greater Kampala region, gives this study an interesting angle to approach this research
problem. The topic of stigma was broached as a potential explanation for an aspect of the study’s
findings: Those on cART often choose to pick up their medication from treatment facilities
which are far from their homes, in order to avoid being seen at an HIV treatment center (Hardon
et al., 2006; Taylor et al., 2014). Those living in proximity to the treatment center may feel a
substantial amount of stigma but may not have the resources to reach a distant treatment facility.
Those who live hours away who decide to invest the resources necessary to reach the JCRC –
which is considered a high-quality treatment center – may be the most invested in treatment
adherence. A similar theory was advanced by Lankowski et al. (2014), in their explanation of
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paradoxical findings whereby greater geographical barriers actually led to positive HIV
treatment outcomes.
In response to the second research question which seeks to assess the relative impact of
demographic variables, our research delivered further counterintuitive findings. From our
statistical models it emerged that the theoretical individual with the highest likelihood of
reporting missed doses lives less than one hour from the treatment facility, has a partner and
high-income employment. The prevalence of HIV stigma also serves as a potential explanation
for these findings. Although stable employment and relationships are considered to be beneficial
for those with chronic conditions such as HIV, non-disclosure of one’s status may negate
potential benefits (Ncama et al., 2008). Those who perceive substantial HIV stigmatization at
home or within their workplaces may not feel comfortable taking their medication, thus
compromising adherence.
Research question (3):
What do individuals on cART perceive to be the main barriers to HIV treatment and treatment
adherence in Kampala, Uganda?
From our interviews with those receiving HIV treatment from the JCRC, it emerged that
the following are notable challenges associated with cART adherence: The community’s
knowledge and perception of HIV and HIV treatment, the burden of the drug regimen, food
insecurity and financial issues, transport and travel, and stigmatization. In general, these
principle barriers were consistent with existing literature on HIV treatment challenges in Uganda
as well as other sub-Saharan African countries such as South Africa (Gilbert & Walker, 2009;
Hardon et al., 2006).
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As described by the participants, the burden of the medication regimen includes the
number and size of pills, the life-long duration of treatment, regimen complexity and resultant
side-effects. This has been difficult address as side-effects can differ drastically between
individuals (Gilbert & Walker, 2009). This challenge associated with cART intersects clearly
with HIV stigma, as many individuals are motivated to take the medication in order to reduce
visible symptoms of the illness in efforts to conceal their HIV status (Schulkind et al., 2016).
Side-effects are also worsened by food insecurity, which is a serious issue in Uganda: A study in
southwestern Uganda found 78.5% of their study participants who were on cART to be food
insecure (Weiser et al., 2010). Food insecurity is generally intertwined with financial insecurity,
whereby those on HIV treatment are often forced to distribute limited funds between the cost of
food, shelter and children’s education, as well as the cost of transportation to the clinic (Tuller et
al., 2010). Indeed, the study’s participants often cited the substantial cost of transportation in
comparison to their living expenses.
6.3 Interrelation of key findings from manuscripts
We advanced several possible explanations for the paradoxical findings from our
quantitative study in Chapter 4. The narrative which emerged from the interviews conducted
with those on cART helps to shed light on the complex relationship between geography and HIV
treatment success. The topic of geographic barriers to treatment adherence was embedded in
several interview questions. However, under the direction of the respondents, it did not remain
the focus of discussion. Rather, the topic of travel and transportation was often re-introduced
when participants discussed fears of stigmatization when taking their medication in transit. As is
commonly identified in qualitative literature, many participants reportedly struggled with the
burden of transportation and geographic mobility (Gilbert & Walker, 2009; Tuller et al., 2010).
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However, the manner in which they dealt with this barrier was not clear cut, and thus, attempts to
measure the association between geography and treatment success may deliver inconsistent
findings. As suggested by the participants, experiences with stigma in transit occurred not only
with travel to treatment facilities, but also during frequent visits to friends and relatives, with
regular travel to home villages, and with jobs which demand high mobility. These are measures
of geographic mobility that have been largely neglected in the literature.
Interview participants also spoke of substantial discrimination within their workplaces.
Many respondents conceal their HIV status at work, and those who disclosed their status faced
severe repercussions such as ostracism and even job loss. These findings in conjunction with the
results of our regression analysis help to explain how employment can actually threaten
treatment adherence. A steady source of income is evidently essential for basic health and wellbeing; however, HIV stigma and discrimination have made it increasingly difficult for people
living with HIV to find employment. People are often forced to take their medication or attend
clinic appointments in secrecy. A study conducted in Kenya and Zambia reported similar
findings, whereby people living with HIV experienced discrimination in hiring, the reception of
promotions, and job loss (Sprague, Simon, & Sprague, 2011).
Lastly, the findings from Chapter 4 suggest that those with a partner were actually more
likely to report missing doses of medication. Although it has been suggested that support from a
significant other should increase treatment adherence, people on cART who haven’t disclosed
their status or are simply uncomfortable with their status can feel pressured to engage in HIV
treatment and care in private (Tsai, Bangsberg, Kegeles, et al., 2013). This emerged from the
interviews as a problem frequently experienced with a particular severity early on in treatment.
People on cART may become more comfortable over time, particularly when the burden of HIV120

related symptoms are reduced (Tsai, Bangsberg, Bwana, et al., 2013). However, early
experiences on cART and initial levels of adherence have implications for long-term treatment
success (Metzner et al., 2009; Ruel et al., 2011). These findings are supported by a study on
treatment adherence in Kampala by Byakika-Tusiime et al. (2005), who found that those who
were single were actually more likely to adhere to treatment.
6.4 Contributions of this dissertation
Literature examining the impact of geographical barriers in urban Uganda has been very
limited, as issues of accessibility in rural areas have often been the focus of study (Lankowski et
al., 2014; Siedner et al., 2013; Tuller et al., 2010). Generally, the specific use of a geographic
approach to examining HIV treatment adherence is rare, regardless of urban or rural context. Our
investigation of predictors of treatment adherence in Kampala contributes to the bridging of this
research gap. This dissertation also contributes to a growing body of literature which endeavors
to incorporate the lived experiences of those on cART into the evaluation of treatment programs.
Our findings help to show how experiences on HIV treatment cannot be understood using a
purely biomedical approach, as such approaches fail to acknowledge the effects of one’s
environment, community and economy on treatment outcomes. By employing perspectives from
health geography, we have provided a holistic interpretation of barriers to treatment success.
This dissertation employed the distinctive approach of coupling regression models with
content analysis, which gives a unique perspective on HIV treatment experiences. Several of our
key findings from Chapter 4 were unexpected, and the perspectives of our interview respondents
allowed us to investigate the social mechanisms which underly our statistical results. This thesis
sheds light on the intersection of social interactions and stigma (at home and in the workplace),
and its negative impact on adherence in Kampala. We have shown how stigmatization can often
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arbitrate the relationship between geography and treatment adherence. Our qualitative findings
also suggest that knowledge levels surrounding HIV and HIV treatment have a powerful
influence on the community’s perception of people living with HIV, and thus, the enactment of
stigmatization.
6.5 Limitations of the study
This thesis has limitations which should be noted. The robustness of findings is heavily
impacted by a study’s sample size (Bohrnstedt & Carter, 1971). As previously discussed, our
sample approaches the minimum expected sample size for logistic regression. Related studies
have also conducted robust analyses using comparable sample sizes (Siedner et al., 2013; Weiser
et al., 2003). However, for future research, a larger sample size could increase the
generalizability of the research in the context of Kampala. Due to time constraints which
required data collection to be complete within four months, probability sampling was not
feasible. However, purposive (non-probability) sampling did allow us to maximize our sample
size during our timeframe and thus optimize the robustness of findings. The purposive sampling
strategy for the selection of interview participants also helped to maximize the richness of
information derived from each case (Palinkas et al., 2015).
Several other limitations should be acknowledged in the consideration of the study’s
findings. Notably, as the majority of the analyses were conducted by the main author of this
dissertation, who is Canadian, our interpretation of findings may be limited. To reduce the
likelihood of misinterpretation, our Ugandan partners were consulted continually throughout the
research process. Still, the influence of the researcher’s positionality and unintentional bias on
research design and analysis should be considered (Phoenix et al., 2013). At various points
throughout the research process, translations between Luganda and English occur. There is
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therefore the possibility of mistranslation, despite the research team’s best efforts. The social
conformity of interview and questionnaire responses also presents a potential limitation, as
participants can feel pressured to give desirable answers, despite assurances that there are no
right or wrong answers. These limitations should be considered in the interpretation of the
findings presented in this dissertation.
6.6 Policy implications
Worldwide, healthcare systems are increasingly adopting models of patient-centered care,
which focus on the unique needs of the patient rather than employing a one-size-fits-all treatment
strategy. This model of healthcare is proposed to have the potential to greatly improve levels of
adherence and thus reduce the development of drug-resistant HIV. Under this model, HIV
treatment patients would be empowered through regular support and counselling (O’Donnell et
al., 2016). One of the findings from this research emphasized the importance of the kindness and
compassion of health personnel for those on cART (pointing to the need for the reinforcement of
professional development), given that several participants explained how they are discouraged to
visit clinics for their medication when they are treated badly in a health facility. The participants’
experiences of stigmatization in the general community can be either alleviated or exacerbated
by their perceived sense of acceptance around health professionals as well as their HIV-positive
peers. Participants expressed a desire to connect with other HIV-positive community members,
with the knowledge that a sense of community can help them to manage the stigma and stress
associated with HIV treatment. These findings point to the need for peer support groups within
the HIV-positive community.
HIV treatment facilities in Uganda have begun to adopt a patient-centered approach and
are therefore working towards increasing the efficiency of healthcare systems (USAID, 2012).
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The JCRC itself strives to employ a differentiated service delivery model (DSDM), which tailors
the cART drug regimen to each patient, providing six months of refills for those with stable
suppressed viral loads (JCRC, 2018). The findings from this study support the application of this
service model in Uganda. However, this treatment strategy can be further improved. For
instance, under current policies, those who experience treatment failure are automatically given
shorter refill periods, requiring them to return to the health center more frequently to be
monitored. For those struggling for transportation costs, this can increase the financial burden
and potentially worsen treatment outcomes. It is therefore recommended for treatment regimens
to be tailored to each individual, with the consideration of the potential influence of factors such
as accessibility on treatment success.
Community-based treatment programs focussed on DSDM have also been shown to
reduce HIV stigma, as those on cART became more open about their HIV status with adequate
support from counsellors (Duffy et al., 2019). Hence, community sensitization should continue to
encourage the public to be increasingly receptive to discussions of HIV and HIV treatment. Our
findings draw attention to the need for increased awareness within the greater community in
Uganda. As confirmed by Uganda’s latest Demographic Health Survey, knowledge levels
surrounding HIV are inadequate: under 50% of the population was assessed as having a
comprehensive understanding of HIV (Uganda Bureau of Statistics & ICF, 2018). The findings
from this study suggest that knowledge levels of HIV treatment are also inadequate. Persistent
misconceptions of HIV and HIV treatment encourage the development of negative stereotypes of
those living with HIV. HIV testing and treatment initiatives have made great strides towards the
goals of achieving universal treatment accessibility and eventually eradicating the virus. Health
education policies should strive to inform the public about HIV risk as well as HIV treatment, as

124

this study’s findings suggest that a substantial proportion of the community is unaware that HIV
is now a manageable chronic condition. Community sensitization can help to reduce the high
levels of stigmatization felt by those on HIV treatment.
6.7 Future directions
This research has provided direction for future studies which may endeavor to explain the
complex relationship between geography and HIV treatment outcomes. Firstly, treatment
outcomes inevitably fluctuate over time, and the personal circumstances of those on treatment do
not necessarily remain constant. Consequently, a longitudinal study which follows participants
on cART will get a clearer picture of factors which impact treatment success. Time-sensitive
analyses are particularly important in this context as adherence to life-long treatment regimens is
suggested to decline over time.
The results of this study have identified stigma as a persistent problem within the
HIV/AIDS epidemic. As health service models in Uganda continue to improve, further research
is needed to assess the degree to which HIV stigma impacts treatment adherence. Additionally,
future studies should endeavour to consider complex social variables that underpin
stigmatization in order to devise appropriate context-based tools for community-level
educational programs aimed at improving public knowledge on HIV treatment.
Lastly, given the importance of the geographical locations of treatment centers, a
location-allocation analysis could be conducted to evaluate the attributes (e.g., transportation,
topography and population characteristics) of potential service areas in order to choose an
optimal location for future treatment clinics. People on HIV treatment in Kampala grapple with
the burden of transportation challenges, but are reluctant to visit treatment centers near their
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home community. A simple model of supply and demand will therefore be inadequate to address
the needs of the population. The development of a comprehensive location-allocation model for
location health facilities will support the advancement of the public health system in the
Kampala region.
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Appendix A

Geography and Health Questionnaire
Name of interviewer: ______________________
Date and time: ______________________
ID Number: ______________________
General Demographic Questions
1. Please circle your identified gender: male

female

other (specify): ________

2. Are you currently enrolled in a research protocol or clinical trial at the JCRC? …………. Y N
3. Do you receive a refund for the cost of your transportation to the JCRC?............................Y N
4. Where do you live in Kampala? Exact address and/or location based on landmarks:

5. Has your residence changed since you started ART treatment?.............................................Y N
If YES, specify the location(s) of your previous home(s):

Employment and Assets
6. Do you own or have use of a car, truck, motorcycle, or bicycle that you use every day for
transportation?……...……………………………………………………………….…….Y N
If YES, circle the type of transport: car, truck, motorcycle, or bicycle
If NO, circle the transport you use most often: private hire, bus, taxi, boda, bicycle, walk
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7. Please indicate which of the following items your household owns (circle your choices).
a. Television
b. Mobile phone
c. Computer
d. Radio
e. Refrigerator
f. Sewing machine
g. Bed
h. Table
i. Running water
j. Electricity
8. Does your household own any livestock?…………………………………………...…….. Y N
If YES, how many of the following animals does your household own?
______Cow(s)
______Goat(s)
______Chicken(s)
______Pig(s)
______Sheep
______Other (specify):

9. Are you employed? ……………………………………………………………………….. Y N
If NO, proceed to sub-section Education and Transportation
10. How many days per week do you work? ______days
11. How many hours per day do you work? ______hours
12. What is the location of your normal place of work? Exact address and/or location based on
landmarks:
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13. How much do you earn (UGX) per month?
a. Below 100,000
b. 100,000 - 349,000
c. 350,000 - 699,000
d. 700,000 - 1,000,000
e. 1,000,000+
14. On average, how long does it take you to get to work? (Circle one option below)
a. Less than 10 min
b. 10 min to 30 min
c. 30 min to 1 hr
d. 1 hr to 2 hrs
e. Greater than 2 hrs
15. What are your typical means of transportation to and from work?
Circle ALL that apply: car, truck, motorcycle, bicycle, private hire, bus, taxi, boda, walk
16. Please list the order of transport and how much time you spend on each transport to/from work
and include waiting times for each transport. (e.g. walk for 10 min to motorcycle, take
motorcycle for 5 min to Shell on Entebbe Rd, wait 15 min for taxi, take taxi for 20 min to taxi
park, wait 5 min for new taxi to take to Wandegeya/work):
To:

From:

17. Has your workplace changed since you started ART treatment? …....………………..…... Y N
If YES, specify the location(s) of your previous workplace(s):

Education and Transportation
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18. Are you in school? That is, secondary, college, vocational, professional, or university? .…Y N
If NO, proceed to sub-section Transportation and Children
19. How many days per week do you attend school? ______days
20. How many hours per day do you attend school? ______hours
21. What school do you attend?

22. What is the location of your school? Exact address and/or location based on landmarks:

23. Have you changed school(s) since you started ART treatment? …………………………...Y N
If YES, specify the location(s) of your previous school(s):

24. On average, how long does it take you to get to school? (Circle one option below)
a. Less than 10 min
b. 10 min to 30 min
c. 30 min to 1 hr
d. 1 hr to 2 hrs
e. Greater than 2 hrs
25. What are your typical means of transportation to school?
Circle ALL that apply: car, truck, motorcycle, bicycle, private hire, bus, taxi, boda, walk
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26. Please list order of transport and how much time you spend on each transport to/from school
and include waiting times for each transport.
To:

From:

Transportation and Children
27. Do you have children?...........................................................................................................Y N
If NO, proceed to sub-section Appointments and HIV-Related Care
28. What school does your child/children attend?

29. What is the location of your child/children’s school? Exact address and/or location based on
landmarks:

30. Do you transport your children TO school?...........................................................................Y N
If YES, how many times per week? _________
31. On average, how much time does it take to drive TO your child/children’s school? (Circle one
option)
a. Less than 10 min
b. 10 min to 30 min
c. 30 min to 1 hr
d. 1 hr to 2 hrs
e. Greater than 2 hrs
32. Do you transport your children FROM school?.....................................................................Y N
If YES, how many times per week? _________
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33. On average, how much time does it take to drive FROM your child/children’s school? (Circle
one option)
a. Less than 10 min
b. 10 min to 30 min
c. 30 min to 1 hr
d. 1 hr to 2 hrs
e. Greater than 2 hrs
34. What are your typical means of transportation to and from your children’s school?
Circle ALL that apply: car, truck, motorcycle, bicycle, private hire, bus, taxi, boda, walk
35. Please list order of transport and how much time you spend on each transport to/from your
children’s school and include waiting times for each transport.
To:

From:

Appointments and HIV-Related Care
36. Is the JCRC your primary clinic for HIV-related care?........................................……….. Y N
If NO, where is your primary medical clinic? Exact address and/or location based on landmarks:

37. How long does it take you to get to your HIV care-related clinic (JCRC or other)?
a. Less than 10 min
b. 10 min to 30 min
c. 30 min to 1 hr
d. 1 hr to 2 hrs
e. Greater than 2 hrs
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38. From which of the following places do you leave most often when heading to the clinic for
HIV-related care? Select one.
a. Home
b. Work
c. School
d. Other (specify): _________________
39. What are your typical means of transportation to/from this clinic?
Circle ALL that apply: car, truck, motorcycle, bicycle, private hire, bus, taxi, boda, walk
40. Please list order of transport and how much time you spend on each transport to/from this clinic
and include waiting times for each transport.
To:

From:

41. How many times per year do you have scheduled clinic visits (at the JCRC or another clinic)?
________ visits
42. Do you ever take the day off of work (or school) to attend your clinic appointments?.........Y N
43. Have you ever missed one of your scheduled clinic visits (at the JCRC or another clinic) while
on firstline treatment? ……………………….……………………………………………. Y N
If YES, how many scheduled clinic visits have you missed in that period? _______ visits
If YES, what was the main reason for missing a clinic visit? Select ONE option.
a. You did not think it was necessary
b. You could not get time off work
c. You needed to fetch your children from school
d. The distance was too far
e. You did not have money for transport there
f. Other (please specify): _________________
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44. Have you changed the clinic you receive your ART drugs from since you started
treatment?................................................................................................................................Y N
If YES, specify the location of your previous clinic(s):

If YES, why did you change your clinic to the current one?

45. Do you get your HIV medications from the same clinic mentioned in questions 36?……. Y N
If YES, proceed to sub-section Treatment Adherence
If NO, where do you pick up your HIV medications from?

46. What are your typical means of transportation to/from this clinic?
Circle ALL that apply: car, truck, motorcycle, bicycle, private hire, bus, taxi, boda, walk
47. Please list order of transport and how much time you spend on each transport to/from this clinic
and include waiting times for each transport.
To:

From:

48. How long does it take you to get to the clinic to pick up your medications?
a. Less than 10 min
b. 10 min to 30 min
c. 30 min to 1 hr
d. 1 hr to 2 hrs
e. Greater than 2 hrs
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49. From which of the following places do you leave most often when heading to the clinic to pick
up your medication? Select one.
a. Home
b. Work
c. School
d. Other (please specify): _________________

Treatment Adherence
50. How often are you scheduled to pick up your HIV medications in a year? _______ times/year
51. Do you ever take the day off of work (or school) to pick up your ART medications?..........Y N
52. Have you ever stopped taking your HIV medicine (intentionally)?…………………....…. Y N
If YES, how long did you stop taking them for? _________ days
If YES, what is the main reason you stopped taking them? Select one option.
a. You felt sick when taking them
b. You feared side-effects
c. You did not feel they were working
d. You feared dependence on the medication
e. You felt better
f. Social stigma
g. Can't take them everyday for the rest of my life
h. Other (please specify): _________________
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53. Have you ever been unable to refill your HIV medicine?......................................................Y N
If YES,
How many times per year have you been unable to refill them? ________ times/year
On average, for how long did you not take your pills because you were unable to refill them?
________ days
What is the main reason you were unable to refill your HIV medicine? Select one option.
a. You could not get time off work
b. You needed to fetch your children from school
c. The distance was too far
d. You did not have money for transport there
e. Your medication was not available at the pharmacy/clinic
f. Other (please specify): _________________
54. Have you ever missed a dose of your medication?................................................................Y N
If YES, what is the main reason you failed to take your pills? Select one option.
a. You were at an important event such as a wedding or funeral
b. You were traveling
c. You were on vacation
d. Your treatment regimen is too complicated
e. You shared or sold your medication
f. You forgot to take it
g. You lost the medication
h. You were hospitalized
i. Other (please specify): _________________
Partner-Related Questions
55. Do you have a primary partner? That is, your husband/wife/boyfriend/girlfriend? ……....Y N
If NO, proceed to sub-section Mental and Physical Health
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56. What is your marital status? Circle one option.
a. Married
b. Separated
c. Widowed
d. With girlfriend/boyfriend
57. Does your partner know your HIV status?.............................................................................Y N
58. Is your partner aware that you are taking ARVs?...................................................................Y N
59. What is your partner’s HIV status?
a. Positive
b. Negative
c. Don’t know
60. Is your partner on ART?.........................................................................................................Y N
If YES, does your partner get their medications from the same place as you?.............................Y N

Mental and Physical Health (Adapted from the Duke Health Profile)
Instructions: Here are some questions about your health and feelings. Please read each
question carefully and check (√) your best answer. You should answer the questions in
your own way. There are no right or wrong answers.
Yes, describes me
exactly

Somewhat
describes me

61. I like who I am

62. I am not an
easy person to
get along with
63. I am basically a
healthy person
64. I give up too
easily
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No, doesn’t
describe me at all

Mental and Physical Health (Adapted from the Duke Health Profile)
Instructions: Here are some questions about your health and feelings. Please read each
question carefully and check (√) your best answer. You should answer the questions in
your own way. There are no right or wrong answers.
Yes, describes me
exactly

Somewhat
describes me

No, doesn’t
describe me at all

65. I have
difficulty
concentrating
66. I am happy
with my family
relationships
67. I am
comfortable
being around
people
TODAY would you have any physical trouble or difficulty:
None

Some

A Lot

68. Walking up a
flight of stairs
69. Running the
length of a
football field
DURING THE PAST WEEK how much trouble have you had with:

None

Some

70. Sleeping

71. Hurting/aching
in any part of
your body
72. Getting tired
easily
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A Lot

Mental and Physical Health (Adapted from the Duke Health Profile)
Instructions: Here are some questions about your health and feelings. Please read each
question carefully and check (√) your best answer. You should answer the questions in
your own way. There are no right or wrong answers.
Yes, describes me
exactly

Somewhat
describes me

No, doesn’t
describe me at all

Some

A Lot

1-4 Days

5-7 Days

73. Feeling
depressed or
sad
74. Nervousness

DURING THE PAST WEEK how often did you:

None
75. Socialize with
other people
(talk or visit
with friends or
relatives)
76. Take part in
social, religious
or recreation
activities
(meetings,
church, sports,
parties)
DURING THE PAST WEEK how often did you:
None

77. Stay in your
home, a nursing
home, or
hospital
because of
sickness, injury,
or other health
problem
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Appendix B
Consent Form

TITLE OF THE RESEARCH:
Geospatial patterns of HIV antiretroviral therapy treatment facility use, work location, and viral
suppression in Kampala, Uganda
PRINCIPAL INVESTIGATOR:
Dr. Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda
Dr. Eric Arts, The University of Western Ontario, London, Canada
INTRODUCTION:
You are being asked to take part in the research study named above. Before you decide whether
to join this study, we would like to explain the purpose of the study, any risks to you, and what
will be expected of you if you decide to participate.
This informed consent document gives you information about the study that will be discussed
with you. Once you understand the study, and if you agree to take part in it, you will be asked to
sign this consent form or make your mark in front of someone. You will be given a copy to keep.
Please note that your participation in this research is entirely voluntary. You may decide not to
take part or to withdraw at any time without losing the benefits of your standard medical care.
PURPOSE OF THE STUDY:
Studies have shown that with the use of repeat clinic visits in Ugandan HIV-infected cohorts the
adherence rates for HIV-infected Ugandans are higher than that of HIV-infected individuals in
North America. Despite this, roughly 10% of Ugandan HIV-infected patients fail first-line cART
which is more than double that of HIV-infected North Americans on cART. The purpose of this
study is to find out whether the geospatial situation of HIV-infected individuals on ARV has an
impact on treatment outcomes
A total of 400 HIV-infected patients from the Kampala district will be in this study. Equal
numbers of patients successful on cART for 3+ years and those who have failed first line cART
within 2 years will be asked to take part in this study.
Procedures:
If you agree to join this study, after you sign this consent form you will be asked questions about
your pattern of transportation use, location of your home and workplace, location of the
pharmacy you receive your ARV drugs from, mental and physical health status and history of
ART adherence. Based on your answers to the survey questions, you may be selected to answer
additional questions about your experience on ART. These additional questions and responses
will be audio recorded and put into writing. We will also review your current clinic charts.
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Potential Benefits:
You will receive UGX 20,000/= (Twenty thousand shillings only) for your transportation costs
to and from the clinic, and for the time you may have lost from work.
Costs to you:
There is no cost to you for taking part in this study.
Confidentiality:
Your research records will be confidential to the extent permitted by law. You will be identified
by a code, and personal information from your records will not be released without your written
permission. You will not be personally identified in any publication about this study. If you are
selected to answer additional questions, your responses will remain confidential. GPS
coordinates will be taken within a 300 m radius of your home to keep anonymity of the exact
location of your home.
Your records may be reviewed by the NIH and the study monitors.
Persons to contact for problems or questions:
If you ever have questions about this study, you should contact Dr. Cissy Kityo at the Joint
Clinical Research Centre in Kampala, Uganda. Tel number xxx xxx-xxx-xxx
If you ever have questions about your rights as a research subject you may call Dr. Jess
Kagimba, Chairman JCRC IRB/REC, Tel number xxx xxx-xxx-xxx or JCRC IRB/REC office on
xxx xxx-xxx-xxx

SIGNATURE PAGE
If you have read the informed consent or had it read and explained to you and understand the
information, and you voluntarily agree to join the study, please sign your name or make your
mark below.

Volunteer’s name

Volunteer’s signature

Date

Witness’ name

Witness’ signature

Date
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Appendix C:
Semi-Structured Interview Guide with ARV User

Name of interviewer: ______________________
Date and time of interview______________________
ID Number: ______________________
Introduction:
-

Introduce interviewer and researchers and reiterate purpose of discussion: We want to
learn from participants, to hear their thoughts on ART and understand challenges that
exist for people who take ARVs

-

Ask for participant’s consent to respond to additional questions which will be audiorecorded and transcribed

-

Thank participants for agreeing to participate, and ensure confidentiality of results

Script: Thank you for accepting to be interviewed for this study, my name is ______, at the jcrc
my role is ______, the purpose of the interview is to try to learn from participants, to hear their
thoughts about ART and understand challenges that exist for people who take ARVs. During the
interview, we ask that you give us as much detail as possible. There are no right or wrong
answers—all answers are welcome. The interview is going to be audio-recorded to help me take
good notes, however, whatever you have said here will only be accessed by the research team
and your names will never be mentioned anywhere outside the interview. After the study, an
analysis will be done and all recordings will be destroyed. Feel free to ask any questions at any
point during the interview. You should also feel free to ask for any clarification you need during
the discussion.
Explore participant’s knowledge of ART:
We would like to understand what people know about HIV/AIDS medicines.
1. Could you help us with this by telling me what you know about antiretroviral therapy (or
ART)?
⎯ Allow patient to say what they want, then probe on the following: how it works,
costs, side effects, how long you have to take it.
⎯ Probe as to whether or not the patient believes ART is a treatment that cures HIV
2. Could you describe what you think may happen when someone on ART misses several
doses of their medication?
⎯ Allow patient to say what they want, then probe on the following: do they become
sick? Do they continue taking this medication?
Understand participant’s experience on ART:
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We would like to hear more about your personal experiences on ART. Please feel free to be open
about the problems you face with this. Everything you say here will remain confidential and will
not be shared with anyone at the clinic.
3. What would you say are the main challenges faced by people on ART?
⎯ Allow patient to say what they want, then probe on the following: side effects,
lack of food, adherence, lifestyle issues, pill burden.
Understand challenges to ART adherence:
We would like to understand how people manage to take their medications – for some people it’s
not a problem but we also know that others don’t always find it easy.
4. Could you tell me what you understand about good adherence?
⎯ Probe: how do you define good adherence?
5. Why do some people have good adherence?
⎯ Probe: what are the sources of motivation for adherence?
6. Why do others have poor adherence?
⎯ Probe: because they forgot to take it? Because they can’t get to the pharmacy?
7. What would you say can be done to help people adhere more easily to their treatment?
⎯ Probe: reminders? Social support?
Quality of HIV/AIDS care and treatment services:
We want to hear your thoughts on the services provided at the JCRC and in Kampala in general.
8. How would you describe the services provided by the JCRC?
⎯ Probe: privacy, confidentiality, respect, being listened to, time spent with patient,
waiting time, integration with other services
9. What support are you given by the health workers to help you adhere better to your
medications?
⎯ Probe especially on counselling about adherence, regular appointments, longer
duration of prescription refill
10. How can existing infrastructure be modified and strengthened to increase access to ART,
in Kampala?
⎯ Probe: transportation, pharmacies.
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Community Perception and Access:
Now we want to hear your experiences with ART in your specific community.
11. What kind of support do you receive from your community, your family, and your
workplace?
⎯ Probe: encouragement from family members? Any negative social support or
stigma? Added stress?
⎯ Specify which family member offers support, probe: boyfriend, husband, children
12. What are the beliefs and perceptions of your community on HIV/AIDS treatment?
⎯ Probe for why they think those beliefs and perceptions exist.
⎯ Probe especially on the existence of stigma or discrimination.
13. What resources are needed to make antiretrovirals widely available in your specific area?
⎯ Probe: more clinics? Improved public transportation?
*Ask follow-up questions based on participant’s responses to questionnaire
Conclude Interview
14. Do you have any questions or feedback for me?
15. Thank the participant and invite them to provide any additional commentary.
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